Professor Philip Barter
Contact Details
Tabs
Publications related to this Person
Book Chapters
Barter P, 2009, 'Evolving Targets of Therapy', in Clinical Lipidology: A Companion to Braunwald's Heart Disease, pp. 387 - 395, http://dx.doi.org/10.1016/B978-141605469-6.50036-6
Barter PJ; Rye KA, 2008, 'HDL and Atherosclerosis', in High-Density Lipoproteins: From Basic Biology to Clinical Aspects, pp. 491 - 505, http://dx.doi.org/10.1002/9783527625178.ch20
Barter PJ, 2006, 'Management of combined hyperlipidemia', in Case Studies in Lipid Management, pp. 95 - 98
Barter P, 2005, 'Overview of HDL and reverse cholesterol transport', in Lipids and Atherosclerosis, pp. 81 - 92
Journal articles
Barter PJ; Yamashita S; Laufs U; Ruiz AJ; Sy R; Fang MDG; Folco E; Libby P; Matsuzawa Y; Santos RD; Santos RD, 2020, 'Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: Insights from a web-based physician survey', Lipids in Health and Disease, vol. 19, pp. 131, http://dx.doi.org/10.1186/s12944-020-01265-z
Schwartz GG; Leiter LA; Ballantyne CM; Barter PJ; Black DM; Kallend D; Laghrissi-Thode F; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Preiss D; Shah PK; Tardif JC; Kittelson J, 2020, 'Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease', Diabetes Care, vol. 43, pp. 1077 - 1084, http://dx.doi.org/10.2337/dc19-2204
Tucker B; McClelland RL; Allison MA; Budoff MJ; Wu BJ; Barter PJ; Rye KA; Ong KL, 2020, 'Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease', Atherosclerosis, vol. 299, pp. 38 - 44, http://dx.doi.org/10.1016/j.atherosclerosis.2020.03.009
Ross R; Neeland IJ; Yamashita S; Shai I; Seidell J; Magni P; Santos RD; Arsenault B; Cuevas A; Hu FB; Griffin BA; Zambon A; Barter P; Fruchart JC; Eckel RH; Matsuzawa Y; Després JP, 2020, 'Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity', Nature Reviews Endocrinology, vol. 16, pp. 177 - 189, http://dx.doi.org/10.1038/s41574-019-0310-7
Salahuddin T; Kittelson J; Tardif JC; Shah PK; Olsson AG; Nicholls SJ; Leitersdorf E; Leiter LA; Kallend D; Black DM; Barter PJ; Ballantyne CM; Schwartz GG, 2020, 'Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial', American Heart Journal, vol. 221, pp. 60 - 66, http://dx.doi.org/10.1016/j.ahj.2019.12.003
Palmer MK; Barter PJ; Lundman P; Nicholls SJ; Toth PP; Karlson BW, 2020, 'Corrigendum to “Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis” [Clin. Biochem. 64 (2019) 24–29](S0009912017311487)(10.1016/j.clinbiochem.2018.10.011)', Clinical Biochemistry, vol. 76, pp. 49, http://dx.doi.org/10.1016/j.clinbiochem.2019.12.006
Wu BJ; Li Y; Ong KL; Sun Y; Johns D; Barter PJ; Rye KA, 2019, 'The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits', Scientific Reports, vol. 9, pp. 16183, http://dx.doi.org/10.1038/s41598-019-52510-0
Magdas A; Ding J; McClelland RL; Allison MA; Barter PJ; Rye KA; Ong KL, 2019, 'The relationship of circulating fibroblast growth factor 21 levels with pericardial fat: The Multi-Ethnic Study of Atherosclerosis', Scientific Reports, vol. 9, pp. 16423, http://dx.doi.org/10.1038/s41598-019-52933-9
Scherer DJ; Nelson AJ; O'Brien R; Kostner KM; Hare DL; Colquhoun DM; Barter PJ; Aylward P; Nicholls SJ; Watts GF, 2019, 'Status of PCSK9 Monoclonal Antibodies in Australia', Heart Lung and Circulation, vol. 28, pp. 1571 - 1579, http://dx.doi.org/10.1016/j.hlc.2019.04.014
Neeland IJ; Ross R; Després JP; Matsuzawa Y; Yamashita S; Shai I; Seidell J; Magni P; Santos RD; Arsenault B; Cuevas A; Hu FB; Griffin B; Zambon A; Barter P; Fruchart JC; Eckel RH, 2019, 'Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement', The Lancet Diabetes and Endocrinology, vol. 7, pp. 715 - 725, http://dx.doi.org/10.1016/S2213-8587(19)30084-1
Hou L; Tang S; Wu BJ; Ong KL; Westerterp M; Barter PJ; Cochran BJ; Tabet F; Rye KA, 2019, 'Apolipoprotein A-l improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1', FASEB Journal, vol. 33, pp. 8479 - 8489, http://dx.doi.org/10.1096/fj.201802512RR
Fruchart JC; Santos RD; Yamashita S; Libby P; Aikawa M; Plutzky J; Pradhan A; Ridker P; Aguilar-Salinas C; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Ruscica M; Després JP; Duriez P; Eckel RH; Ezhov MV; Farnier M; Ginsberg HN; Hermans MP; Ishibashi S; Karpe F; Kodama T; Koenig W; Krempf M; Lim S; Lorenzatti AJ; McPherson R; Nuñez-Cortes JM; Nordestgaard BG; Ogawa H; Packard CJ; Ponte-Negretti CI; Reiner Ž; Sadikot S; Shimano H; Sritara P; Stock JK; Su TC; Susekov AV; Tartar A; Taskinen MR; Tenenbaum A; Tokgözoğlu LS; Tomlinson B; Tybjærg-Hansen A; Valensi P; Vrablík M; Wahli W; Watts GF; Yokote K; Zambon A, 2019, 'Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?', Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 13, pp. 2723 - 2725, http://dx.doi.org/10.1016/j.dsx.2019.05.034
Fruchart JC; Santos RD; Aguilar-Salinas C; Aikawa M; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Després JP; Duriez P; Eckel RH; Ezhov MV; Farnier M; Ginsberg HN; Hermans MP; Ishibashi S; Karpe F; Kodama T; Koenig W; Krempf M; Lim S; Lorenzatti AJ; McPherson R; Nuñez-Cortes JM; Nordestgaard BG; Ogawa H; Packard CJ; Plutzky J; Ponte-Negretti CI; Pradhan A; Ray KK; Reiner Z; Ridker PM; Ruscica M; Sadikot S; Shimano H; Sritara P; Stock JK; Su TC; Susekov AV; Tartar A; Taskinen MR; Tenenbaum A; Tokgözoǧlu LS; Tomlinson B; Tybjærg-Hansen A; Valensi P; Vrablík M; Wahli W; Watts GF; Yamashita S; Yokote K; Zambon A; Libby P, 2019, 'The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential', Cardiovascular Diabetology, vol. 18, http://dx.doi.org/10.1186/s12933-019-0864-7
Wu BJ; Sun Y; Ong KL; Li Y; Tang S; Barter PJ; Rye KA, 2019, 'Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 39, pp. 1160 - 1171, http://dx.doi.org/10.1161/ATVBAHA.118.312282
Ong KL; Hui N; Januszewski AS; Kaakoush NO; Xu A; Fayyad R; DeMicco DA; Jenkins AJ; Keech AC; Waters DD; Barter PJ; Rye KA, 2019, 'High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)', Metabolism: Clinical and Experimental, vol. 93, pp. 93 - 99, http://dx.doi.org/10.1016/j.metabol.2018.11.006
Barter P; Genest J, 2019, 'HDL cholesterol and ASCVD risk stratification: A debate', Atherosclerosis, vol. 283, pp. 7 - 12, http://dx.doi.org/10.1016/j.atherosclerosis.2019.01.001
Cochran B; Tang S; Tabet F; Cuesta Torres L; Wu B; Barter P; Rye K-A, 2019, 'Apolipoprotein A-I enhances insulin-dependent and insulinindependent glucose uptake by skeletal muscle', Scientific Reports, vol. 9, http://dx.doi.org/10.1038/s41598-018-38014-3
Ong KL; McClelland RL; Allison MA; Kokkinos J; Wu BJ; Barter PJ; Rye KA, 2019, 'Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 281, pp. 200 - 206, http://dx.doi.org/10.1016/j.atherosclerosis.2018.10.011
Palmer MK; Barter PJ; Lundman P; Nicholls SJ; Toth PP; Karlson BW, 2019, 'Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis', Clinical Biochemistry, vol. 64, pp. 24 - 29, http://dx.doi.org/10.1016/j.clinbiochem.2018.10.011
Hui N; Barter PJ; Ong KL; Rye KA, 2019, 'Altered HDL metabolism in metabolic disorders: Insights into the therapeutic potential of HDL', Clinical Science, vol. 133, pp. 2221 - 2235, http://dx.doi.org/10.1042/CS20190873
Shapiro JD; Thavaneswaran S; Underhill CR; Robledo KP; Karapetis CS; Day FL; Nott LM; Jefford M; Chantrill LA; Pavlakis N; Tebbutt NC; Price TJ; Khasraw M; Van Hazel GA; Waring PM; Tejpar S; Simes J; Gebski VJ; Desai J; Segelov E, 2018, 'Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study', Clinical Colorectal Cancer, vol. 17, pp. 313 - 319, http://dx.doi.org/10.1016/j.clcc.2018.06.002
Barter PJ; Cochran BJ; Rye KA, 2018, 'CETP inhibition, statins and diabetes', Atherosclerosis, vol. 278, pp. 143 - 146, http://dx.doi.org/10.1016/j.atherosclerosis.2018.09.033
Field KM; Fitt G; Rosenthal MA; Simes J; Nowak AK; Barnes EH; Sawkins K; Goh C; Moffat BA; Salinas S; Cher L; Wheeler H; Hovey EJ; Phal PM, 2018, 'Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. e359 - e365, http://dx.doi.org/10.1111/ajco.12806
Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE, 2018, 'Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial', Clinical Cardiology, vol. 41, pp. 1281 - 1288, http://dx.doi.org/10.1002/clc.23055
Karlson BW; Nicholls SJ; Lundman P; Barter PJ; Palmer MK, 2018, 'Modeling statin-induced reductions of cardiovascular events in primary prevention: A VOYAGER meta-analysis', Cardiology (Switzerland), vol. 140, pp. 30 - 34, http://dx.doi.org/10.1159/000488311
Martin AJ; Gibbs E; Sjoquist K; Pavlakis N; Simes J; Price T; Shannon J; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Kim JW; Goldstein D, 2018, 'Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma', Gastric Cancer, vol. 21, pp. 473 - 480, http://dx.doi.org/10.1007/s10120-017-0754-1
Barter PJ; Rye KA, 2018, 'Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk', Cardiology Clinics, vol. 36, pp. 299 - 310, http://dx.doi.org/10.1016/j.ccl.2017.12.011
Tarnow-Mordi W; Morris J; Kirby A; Robledo K; Askie L; Brown R; Evans N; Finlayson S; Fogarty M; Gebski V; Ghadge A; Hague W; Isaacs D; Jeffery M; Keech A; Kluckow M; Popat H; Sebastian L; Aagaard K; Belfort M; Pammi M; Abdel-Latif M; Reynolds G; Ariff S; Sheikh L; Chen Y; Colditz P; Liley H; Pritchard M; De Luca D; De Waal K; Forder P; Duley L; El-Naggar W; Gill A; Newnham J; Simmer K; Groom K; Weston P; Gullam J; Patel H; Koh G; Lui K; Marlow N; Morris S; Sehgal A; Wallace E; Soll R; Young L; Sweet D; Walker S; Watkins A; Wright I; Osborn D; Simes J, 2018, 'Delayed Versus Immediate Cord Clamping in Preterm Infants', Obstetrical and Gynecological Survey, vol. 73, pp. 265 - 266, http://dx.doi.org/10.1097/01.ogx.0000534708.24689.e0
Jonker DJ; Nott L; Yoshino T; Gill S; Shapiro J; Ohtsu A; Zalcberg J; Vickers MM; Wei AC; Gao Y; Tebbutt NC; Markman B; Price T; Esaki T; Koski S; Hitron M; Li W; Li Y; Magoski NM; Li CJ; Simes J; Tu D; O'Callaghan CJ, 2018, 'Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 263 - 270, http://dx.doi.org/10.1016/S2468-1253(18)30009-8
Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ, 2018, 'Visit-to-visit variability of lipid measurements as predictors of cardiovascular events', Journal of Clinical Lipidology, vol. 12, pp. 356 - 366, http://dx.doi.org/10.1016/j.jacl.2017.12.003
Choteau SA; Cuesta Torres LF; Barraclough JY; Elder AMM; Martínez GJ; Chen Fan WY; Shrestha S; Ong KL; Barter PJ; Celermajer DS; Rye KA; Patel S; Tabet F, 2018, 'Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease', International Journal of Cardiology, vol. 253, pp. 138 - 144, http://dx.doi.org/10.1016/j.ijcard.2017.09.190
Rankin NM; Lai M; Miller D; Beale P; Spigelman A; Prest G; Turley K; Simes J, 2018, 'Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. 74 - 83, http://dx.doi.org/10.1111/ajco.12765
Hui TH; McClelland RL; Allison MA; Rodriguez CJ; Kronmal RA; Heckbert SR; Michos ED; Barter PJ; Rye KA; Ong KL, 2018, 'The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 269, pp. 86 - 91, http://dx.doi.org/10.1016/j.atherosclerosis.2017.12.026
Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J, 2018, 'Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: Analysis of the dal-outcomes randomized clinical trial', JAMA Cardiology, vol. 3, pp. 164 - 168, http://dx.doi.org/10.1001/jamacardio.2017.3833
Lee CK; Hudson M; Simes J; Ribi K; Bernhard J; Coates AS, 2018, 'When do patient reported quality of life indicators become prognostic in breast cancer?', Health and Quality of Life Outcomes, vol. 16, http://dx.doi.org/10.1186/s12955-017-0834-2
Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G, 2018, 'Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk', Journal of Clinical Lipidology, vol. 12, pp. 130 - 136, http://dx.doi.org/10.1016/j.jacl.2017.10.001
Rosenson RS; Brewer HB; Barter PJ; Björkegren JLM; Chapman MJ; Gaudet D; Kim DS; Niesor E; Rye KA; Sacks FM; Tardif JC; Hegele RA, 2018, 'HDL and atherosclerotic cardiovascular disease: Genetic insights into complex biology', Nature Reviews Cardiology, vol. 15, pp. 9 - 19, http://dx.doi.org/10.1038/nrcardio.2017.115
Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ, 2018, 'Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin', Journal of the American Heart Association, vol. 7, http://dx.doi.org/10.1161/JAHA.117.007387
Shrestha S; Wu BJ; Guiney L; Barter PJ; Rye KA, 2018, 'Cholesteryl ester transfer protein and its inhibitors', Journal of Lipid Research, vol. 59, pp. 772 - 783, http://dx.doi.org/10.1194/jlr.R082735
Vallejo-Vaz AJ; Fayyad R; Matthijs Boekholdt S; Kees Hovingh G; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK, 2018, 'Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial', Circulation, vol. 138, pp. 770 - 781, http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032318
Barter PJ, 2018, 'High- versus low-dose statin: Effects on cardiovascular events and all-cause death', Circulation, vol. 137, pp. 2013 - 2015, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034407
Alshamiri M; Ghanaim MMA; Barter P; Chang KC; Li JJ; Matawaran BJ; Santoso A; Shaheen S; Suastika K; Thongtang N; Yusof AKM, 2018, 'Expert opinion on the applicability of dyslipidemia guidelines in Asia and the middle east', International Journal of General Medicine, vol. 11, pp. 313 - 322, http://dx.doi.org/10.2147/IJGM.S160555
Barter PJ; Waters DD, 2018, 'Variations in time to benefit among clinical trials of cholesterol-lowering drugs', Journal of Clinical Lipidology, vol. 12, pp. 857 - 862, http://dx.doi.org/10.1016/j.jacl.2018.04.006
van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA, 2017, 'Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study', Cancer Chemotherapy and Pharmacology, vol. 80, pp. 1209 - 1217, http://dx.doi.org/10.1007/s00280-017-3451-1
Chung RWS; Wang Z; Bursill CA; Wu BJ; Barter PJ; Rye KA, 2017, 'Effect of long-term dietary sphingomyelin supplementation on atherosclerosis in mice', PLoS ONE, vol. 12, http://dx.doi.org/10.1371/journal.pone.0189523
Driscoll A; Barnes EH; Blankenberg S; Colquhoun DM; Hunt D; Nestel PJ; Stewart RA; West MJ; White HD; Simes J; Tonkin A, 2017, 'Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model', International Journal of Cardiology, vol. 248, pp. 361 - 368, http://dx.doi.org/10.1016/j.ijcard.2017.06.098
Stewart RAH; Colquhoun DM; Marschner SL; Kirby AC; Simes J; Nestel PJ; Glozier N; O'Neil A; Oldenburg B; White HD; Tonkin AM, 2017, 'Persistent psychological distress and mortality in patients with stable coronary artery disease', Heart, vol. 103, pp. 1860 - 1866, http://dx.doi.org/10.1136/heartjnl-2016-311097
Karlson BW; Palmer MK; Nicholls SJ; Barter PJ; Lundman P, 2017, 'Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database', Atherosclerosis, vol. 265, pp. 54 - 59, http://dx.doi.org/10.1016/j.atherosclerosis.2017.08.014
Bowman L; Hopewell JC; Chen F; Wallendszus K; Stevens W; Collins R; Wiviott SD; Cannon CP; Braunwald E; Sammons E; Landray MJ; Jiang L; Armitage J; Haynes R; Maggioni AP; Angermann CE; Ertl G; Wanner C; Pedersen T; Goto S; Teramoto T; Baigent C; Barter P; Chen Y; Chen Z; Gray A; Mihaylova B; Sleight P; Tobert J; Blaustein R; DeLucca P; Mitchel Y; van Leijenhorst G; Sandercock P; DeMets D; Kjekshus J; Neuberger J; Tonkin A; Emberson J; Granger C; Colhoun H; Barton J; Bray C; Dayanandan R; Knott C; Lay M; Murphy K; Wincott E; Achiri P; Barry S; Bateman S; Brewster A; Briggs S; Brown R; Burke A; Butler E; Cobb L; Collet A; Crowther J; Cureton L; Danesh-Pour S; Fathers S; Fletcher L; Frederick K; Gordon T; Gray M; Heineman J; Howard S; Jackson D; Lam N; Lee R; Machin O; Madgwick Z; Matthewson M; Nolan J; Nunn M; Panicker A; Pank L; Pearson-Burton E; Pickworth S; Qiao Y; Radley A; Roby K; Sayer J; Shah S; Taylor K; Thorne H; Timadjer A; Vandenberg K; Wickman M; Willett M; Woods J; Yu H; Aung T; Bulbulia R; Clarke R; Herrington W; Judge P; Lewis D; Llewellyn-Bennett R, 2017, 'Effects of anacetrapib in patients with atherosclerotic vascular disease', New England Journal of Medicine, vol. 377, pp. 1217 - 1227, http://dx.doi.org/10.1056/NEJMoa1706444
Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H, 2017, 'The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)', Cancer, vol. 123, pp. 3576 - 3582, http://dx.doi.org/10.1002/cncr.30838
Won KB; Hur SH; Nam CW; Ann SH; Park GM; Lee SG; Kim HE; Cho YK; Yoon HJ; Park HS; Kim H; Han S; Jeong MH; Ahn YK; Rha SW; Kim CJ; Cho MC; Kim HS; Chae SC; Kim KS; Kim YJ; Kim KB; Barter P, 2017, 'Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction', Medicine (United States), vol. 96, http://dx.doi.org/10.1097/MD.0000000000007180
Hovey EJ; Field KM; Rosenthal MA; Barnes EH; Cher L; Nowak AK; Wheeler H; Sawkins K; Livingstone A; Phal P; Goh C; Simes J; Kelly P; Hayden A; Barnes E; Espinoza D; Brown C; Winter D; Tomes B; Pike R; Simes J; Garrett L; Kilsby H; Freilich R; Arzhintar I; Dowling A; Ranieri N; Jennens R; Osmond F; Patterson KW; Phay A; Byrne A; Begbie S; Williams P; Kirby-Lewis S; Abell F; Plowman L; Flynn J; Inglis P; Ives A; Lobb S; Lwin Z; Woodward N; Crosbie G; Singhal N; Smith S; Whelan M, 2017, 'Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: An exploratory randomized phase II trial', Neuro-Oncology Practice, vol. 4, pp. 171 - 181, http://dx.doi.org/10.1093/nop/npw025
Barter PJ; Rye KA, 2017, 'HDL cholesterol concentration or HDL function: Which matters?', European Heart Journal, vol. 38, pp. 2487 - 2489, http://dx.doi.org/10.1093/eurheartj/ehx274
Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ, 2017, 'Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN', Atherosclerosis, vol. 263, pp. 137 - 144, http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.026
van Capelleveen JC; Bochem AE; Boekholdt SM; Mora S; Hoogeveen RC; Ballantyne CM; Ridker PM; Sun W; Barter PJ; Tall AR; Zwinderman AH; Kastelein JJP; Wareham NJ; Khaw KT; Hovingh GK, 2017, 'Association of high-density lipoprotein-cholesterol versus apolipoprotein A-I with risk of coronary heart disease: The European prospective investigation into cancer-norfolk prospective population study, the atherosclerosis risk in communities study, and the Women'S Health Study', Journal of the American Heart Association, vol. 6, http://dx.doi.org/10.1161/JAHA.117.006636
Leong T; Smithers BM; Haustermans K; Michael M; Gebski V; Miller D; Zalcberg J; Boussioutas A; Findlay M; O’Connell RL; Verghis J; Willis D; Kron T; Crain M; Murray WK; Lordick F; Swallow C; Darling G; Simes J; Wong R, 2017, 'TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG', Annals of Surgical Oncology, vol. 24, pp. 2252 - 2258, http://dx.doi.org/10.1245/s10434-017-5830-6
Field KM; King MT; Simes J; Espinoza D; Barnes EH; Sawkins K; Rosenthal MA; Cher L; Hovey E; Wheeler H; Nowak AK, 2017, 'Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma', Journal of Neuro-Oncology, vol. 133, pp. 623 - 631, http://dx.doi.org/10.1007/s11060-017-2479-8
Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B; Colman PG; Best JD; Simes JR; Rye KA; Keech AC, 2017, 'Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study', Clinical Chemistry, vol. 63, pp. 1261 - 1270, http://dx.doi.org/10.1373/clinchem.2016.270876
Bagdade J; Barter P; Quiroga C; Alaupovic P, 2017, 'Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial)', American Journal of Cardiology, vol. 119, pp. 1753 - 1756, http://dx.doi.org/10.1016/j.amjcard.2017.02.049
Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Wolski K; Ruotolo G; Vangerow B; Weerakkody G; Goodman SG; Conde D; McGuire DK; Nicolau JC; Leiva-Pons JL; Pesant Y; Li W; Kandath D; Kouz S; Tahirkheli N; Mason D; Nissen SE, 2017, 'Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease', New England Journal of Medicine, vol. 376, pp. 1933 - 1942, http://dx.doi.org/10.1056/NEJMoa1609581
Cochran BJ; Ryder W; parmar A; Meikle S; Barter P; Rye K, 2017, 'Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT', Journal of Visualized Experiments, vol. 2017, http://dx.doi.org/10.3791/55184
Bowman L; Chen F; Sammons E; Hopewell JC; Wallendszus K; Stevens W; Valdes-Marquez E; Wiviott S; Cannon CP; Braunwald E; Collins R; Landray MJ; Hopewell JC; Jiang L; Armitage J; Haynes R; Maggioni AP; Ertl G; Angermann CE; Pedersen T; Goto S; Teramoto T; Gray A; Mihaylova B; Baigent C; Barter P; Chen Y; Chen Z; Tobert J; Sleight P; Blaustein R; DeLucca P; Mitchel Y; van Leijenhorst G; Sandercock P; DeMets D; Kjekshus J; Neuberger J; Tonkin A; Emberson J; Granger C; Colhoun H, 2017, 'Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics', American Heart Journal, vol. 187, pp. 182 - 190, http://dx.doi.org/10.1016/j.ahj.2017.02.021
Wetzig N; Gill PG; Espinoza D; Mister R; Stockler MR; Gebski VJ; Ung OA; Campbell I; Simes J, 2017, 'Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema', Annals of Surgical Oncology, vol. 24, pp. 1064 - 1070, http://dx.doi.org/10.1245/s10434-016-5669-2
Pandzic E; Gelissen IC; Whan R; Barter PJ; Sviridov D; Gaus K; Rye KA; Cochran BJ, 2017, 'The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/srep42025
Cochran BJ; Hou L; Manavalan APC; Moore BM; Tabet F; Sultana A; Torres LC; Tang S; Shrestha S; Senanayake P; Patel M; Ryder WJ; Bongers A; Maraninchi M; Wasinger VC; Westerterp M; Tall AR; Barter PJ; Rye K-A, 2017, 'Impact of Perturbed Pancreatic beta-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism (vol 65, pg 3610, 2016)', DIABETES, vol. 66, pp. 560 - 560, http://dx.doi.org/10.2337/db17-er02b
Pitts R; Gunzburger E; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; Nicholls SJ; Shah PK; Tardif JC; Olsson AG; McMurray JJV; Kittelson J; Schwartz GG, 2017, 'Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure', Journal of the American Heart Association, vol. 6, http://dx.doi.org/10.1161/JAHA.116.004119
Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA, 2017, 'Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 37, pp. 2333 - 2341, http://dx.doi.org/10.1161/ATVBAHA.117.310051
Al Sayed N; Al Waili K; Alawadi F; Al-Ghamdi S; Al Mahmeed W; Al-Nouri F; Al Rukhaimi M; Al-Rasadi K; Awan Z; Farghaly M; Hassanein M; Sabbour H; Zubaid M; Barter P, 2016, 'Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East', International Journal of Cardiology, vol. 225, pp. 268 - 283, http://dx.doi.org/10.1016/j.ijcard.2016.09.081
Pitts R; Gunzburger E; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Niesor EJ; Olsson AG; Shah PK; Tardif JC; Kittelson J; Schwartz GG, 2016, 'Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein', Journal of the American College of Cardiology, vol. 68, pp. 2488 - 2490, http://dx.doi.org/10.1016/j.jacc.2016.09.932
Cochran BJ; Hou L; Manavalan APC; Moore BM; Tabet F; Sultana A; Torres LC; Tang S; Shrestha S; Senanayake P; Patel M; Ryder WJ; Bongers A; Maraninchi M; Wasinger VC; Westerterp M; Tall AR; Barter PJ; Rye KA, 2016, 'Impact of perturbed pancreatic β-cell cholesterol homeostasis on adipose tissue and skeletal muscle metabolism', Diabetes, vol. 65, pp. 3610 - 3620, http://dx.doi.org/10.2337/db16-0668
Alshehry ZH; Mundra PA; Barlow CK; Mellett NA; Wong G; McConville MJ; Simes J; Tonkin AM; Sullivan DR; Barnes EH; Nestel PJ; Kingwell BA; Marre M; Neal B; Poulter NR; Rodgers A; Williams B; Zoungas S; Hillis GS; Chalmers J; Woodward M; Meikle PJ, 2016, 'Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus', Circulation, vol. 134, pp. 1637 - 1650, http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023233
Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D; Evans S; Law M; MacMahon S; Martin S; Neal B; Poulter N; Preiss D; Ridker P; Roberts I; Rodgers A; Sandercock P; Schulz K; Sever P; Simes J; Smeeth L; Wald N; Yusuf S; Peto R, 2016, 'Interpretation of the evidence for the efficacy and safety of statin therapy', The Lancet, vol. 388, pp. 2532 - 2561, http://dx.doi.org/10.1016/S0140-6736(16)31357-5
Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC; Folco E; Freiberger T; Genest J; Hovingh GK; Harada-Shiba M; Humphries SE; Jackson AS; Mata P; Moriarty PM; Raal FJ; Al-Rasadi K; Ray KK; Reiner Z; Sijbrands EJG; Yamashita S, 2016, 'Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel', The Lancet Diabetes and Endocrinology, vol. 4, pp. 850 - 861, http://dx.doi.org/10.1016/S2213-8587(16)30041-9
Karlson BW; Wiklund O; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: Results from VOYAGER', European Heart Journal - Cardiovascular Pharmacotherapy, vol. 2, pp. 212 - 217, http://dx.doi.org/10.1093/ehjcvp/pvw006
Herrington WG; Emberson J; Mihaylova B; Blackwell L; Reith C; Solbu MD; Mark PB; Fellström B; Jardine AG; Wanner C; Holdaas H; Fulcher J; Haynes R; Landray MJ; Keech A; Simes J; Collins R; Baigent C, 2016, 'Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials', The Lancet Diabetes and Endocrinology, vol. 4, pp. 829 - 839, http://dx.doi.org/10.1016/S2213-8587(16)30156-5
Cochran BJ; Ryder WJ; Parmar A; Tang S; Reilhac A; Arthur A; Charil A; Hamze H; Barter PJ; Kritharides L; Meikle SR; Gregoire MC; Rye KA, 2016, 'In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes', Diabetologia, vol. 59, pp. 1977 - 1984, http://dx.doi.org/10.1007/s00125-016-3993-5
Al Rasadi K; Almahmeed W; AlHabib KF; Abifadel M; Farhan HA; AlSifri S; Jambart S; Zubaid M; Awan Z; Al-Waili K; Barter P, 2016, 'Dyslipidaemia in the Middle East: Current status and a call for action', Atherosclerosis, vol. 252, pp. 182 - 187, http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.925
Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D, 2016, 'Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial', Journal of Clinical Oncology, vol. 34, pp. 2728 - 2735, http://dx.doi.org/10.1200/JCO.2015.65.1901
Geronimo FRB; Barter PJ; Rye KA; Heather AK; Shearston KD; Rodgers KJ, 2016, 'Plaque stabilizing effects of apolipoprotein A-IV', Atherosclerosis, vol. 251, pp. 39 - 46, http://dx.doi.org/10.1016/j.atherosclerosis.2016.04.019
Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, vol. 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4
Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; Van Hazel G; Wilson K; Simes J; Shapiro JD, 2016, 'Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study', Journal of Clinical Oncology, vol. 34, pp. 2258 - 2264, http://dx.doi.org/10.1200/JCO.2015.65.6843
Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; Van Hall G; Cobelli C; Dalla-Man C; Otvos JD; Rye KA; Johansson J; Gordon A; Wong NCW; Sviridov D; Barter P; Duffy SJ; Meikle PJ; Kingwell BA, 2016, 'Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial', Metabolism: Clinical and Experimental, vol. 65, pp. 904 - 914, http://dx.doi.org/10.1016/j.metabol.2016.03.002
Reith C; Blackwell L; Emberson J; Mihaylova B; Armitage J; Fulcher J; Keech A; Simes J; Baigent C; Collins R, 2016, 'Protocol for analyses of adverse event data from randomized controlled trials of statin therapy', American Heart Journal, vol. 176, pp. 63 - 69, http://dx.doi.org/10.1016/j.ahj.2016.01.016
Liu G; Tu D; Lewis M; Cheng D; Sullivan LA; Chen Z; Morgen E; Simes J; Price TJ; Tebbutt NC; Shapiro JD; Jeffery GM; Mellor JD; Mikeska T; Virk S; Shepherd LE; Jonker DJ; O'Callaghan CJ; Zalcberg JR; Karapetis CS; Dobrovic A, 2016, 'Fc-g receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer', Clinical Cancer Research, vol. 22, pp. 2435 - 2444, http://dx.doi.org/10.1158/1078-0432.CCR-15-0414
Hague WE; Simes J; Kirby A; Keech AC; White HD; Hunt D; Nestel PJ; Colquhoun DM; Pater H; Stewart RA; Sullivan DR; Thompson PL; West M; Glasziou PP; Tonkin AM, 2016, 'Long-term effectiveness and safety of pravastatin in patients with coronary heart disease', Circulation, vol. 133, pp. 1851 - 1860, http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018580
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients with Hypertriglyceridemia', American Journal of Cardiology, vol. 117, pp. 1444 - 1448, http://dx.doi.org/10.1016/j.amjcard.2016.02.011
Barter PJ; Rye KA, 2016, 'Coronary artery disease: Scavenger receptor class B1-a target to reduce CHD risk?', Nature Reviews Cardiology, vol. 13, pp. 249 - 250, http://dx.doi.org/10.1038/nrcardio.2016.50
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis', European Journal of Preventive Cardiology, vol. 23, pp. 744 - 747, http://dx.doi.org/10.1177/2047487315598710
Barter PJ; Rye KA, 2016, 'New era of lipid-lowering drugs', Pharmacological Reviews, vol. 68, pp. 458 - 475, http://dx.doi.org/10.1124/pr.115.012203
Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C; Loi S; Marschner I; Simes J; De Souza P, 2016, 'Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer', Journal of Clinical Oncology, vol. 34, pp. 936 - 944, http://dx.doi.org/10.1200/JCO.2015.62.4767
Sultana A; Cochran BJ; Tabet F; Patel M; Cuesta Torres L; Barter PJ; Rye K, 2016, 'Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I', The FASEB Journal, vol. 30, pp. 2324 - 2335, http://dx.doi.org/10.1096/fj.201500026R
Barter PJ; Rye KA, 2016, 'Cholesteryl ester transfer protein inhibition is not yet dead - Pro', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, pp. 439 - 441, http://dx.doi.org/10.1161/ATVBAHA.115.306879
Tabet F; Torres LFC; Ong KL; Shrestha S; Choteau SA; Barter PJ; Clifton P; Rye KA, 2016, 'High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0151061
Puranik R; Bao S; Bonin AM; Kaur R; Weder JE; Casbolt L; Hambley TW; Lay PA; Barter PJ; Rye KA, 2016, 'A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo', Cell and Bioscience, vol. 6, http://dx.doi.org/10.1186/s13578-016-0076-8
Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Hu B; Uno K; Kataoka Y; Herrman JPR; Merkely B; Borgman M; Nissen SE, 2016, 'Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial', American Journal of Cardiovascular Drugs, vol. 16, pp. 55 - 65, http://dx.doi.org/10.1007/s40256-015-0146-z
Rye KA; Barter PJ; Cochran BJ, 2016, 'Apolipoprotein A-I interactions with insulin secretion and production', Current Opinion in Lipidology, vol. 27, pp. 8 - 13, http://dx.doi.org/10.1097/MOL.0000000000000253
Rosenson RS; Brewer HB; Ansell BJ; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR, 2016, 'Dysfunctional HDL and atherosclerotic cardiovascular disease', Nature Reviews Cardiology, vol. 13, pp. 48 - 60, http://dx.doi.org/10.1038/nrcardio.2015.124
Barter P; Janus E; Matsuzawa Y; Su TC; Sy R; Tomlinson B; Yamashita S; Yeh HL, 2016, 'Professor Philip Yu-An Ding 1949-2015', Journal of atherosclerosis and thrombosis, vol. 23, pp. 1367, http://dx.doi.org/10.5551/jat.MR001
Rye KA; Barter PJ; Brown AJ, 2015, 'Speed kills in more ways than one: Methamphetamine and atherosclerosis', Atherosclerosis, vol. 243, pp. 654 - 655, http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.034
Barter PJ; Rye KA, 2015, 'Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?', Clinical Therapeutics, vol. 37, pp. 2716 - 2731, http://dx.doi.org/10.1016/j.clinthera.2015.07.021
Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Riesmeyer J; Vangerow B; Ruotolo G; Weerakkody GJ; Nissen SE, 2015, 'Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial', American Heart Journal, vol. 170, pp. 1061 - 1069, http://dx.doi.org/10.1016/j.ahj.2015.09.007
Whittle JR; Lickliter JD; Gan HK; Scott AM; Simes J; Solomon BJ; MacDiarmid JA; Brahmbhatt H; Rosenthal MA, 2015, 'First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma', Journal of Clinical Neuroscience, vol. 22, pp. 1889 - 1894, http://dx.doi.org/10.1016/j.jocn.2015.06.005
Chandrasegaram MD; Goldstein D; Simes J; Gebski V; Kench JG; Gill AJ; Samra JS; Merrett ND; Richardson AJ; Barbour AP; Fawcett J; Grimison PS; Christophi C; Padbury R; Haghighi KS; Chen JW; Nikfarjam M; O'Rourke N; Spry N, 2015, 'Meta-analysis of radical resection rates and margin assessment in pancreatic cancer', British Journal of Surgery, vol. 102, pp. 1459 - 1472, http://dx.doi.org/10.1002/bjs.9892
Bisoendial R; Tabet F; Tak PP; Petrides F; Torres LFC; Hou L; Cook A; Barter PJ; Weninger W; Rye KA, 2015, 'Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, pp. 2443 - 2450, http://dx.doi.org/10.1161/ATVBAHA.115.305777
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CSB; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; Rosenthal MA; Arzhintar I; Garrett L; Byrne A; Dowling A; Ranieri N; Jennens R; Osmond F; Patterson WK; Phay A; Abell F; Plowman L; Flynn J; Hovey E; Kilsby H; Kirby-Lewis S; Singhal N; Smith S; Whelan M; Inglis P; Ives A; Nowak A; Lobb S; Begbie S; Williams P; Lwin Z; Woodward N; Crosbie G; Harrup R; Pyszkowski L; Gauden S; Neville A, 2015, 'Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma', Neuro-Oncology, vol. 17, pp. 1504 - 1513, http://dx.doi.org/10.1093/neuonc/nov104
Barter PJ; Tabet F; Rye KA, 2015, 'Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?', Journal of lipid research, vol. 56, pp. 2045 - 2047, http://dx.doi.org/10.1194/jlr.C063768
Tonkin AM; Blankenberg S; Kirby A; Zeller T; Colquhoun DM; Funke-Kaiser A; Hague W; Hunt D; Keech AC; Nestel P; Stewart R; Sullivan DR; Thompson PL; West M; White HD; Simes J, 2015, 'Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study', International Journal of Cardiology, vol. 201, pp. 499 - 507, http://dx.doi.org/10.1016/j.ijcard.2015.07.080
Stevenson ARL; Solomon MJ; Lumley JW; Hewett P; Clouston AD; Gebski VJ; Davies L; Wilson K; Hague W; Simes J, 2015, 'Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial', JAMA - Journal of the American Medical Association, vol. 314, pp. 1356 - 1363, http://dx.doi.org/10.1001/jama.2015.12009
Wain LV; Shrine N; Miller S; Jackson VE; Ntalla I; Artigas MS; Billington CK; Kheirallah AK; Allen R; Cook JP; Probert K; Obeidat M; Bossé Y; Hao K; Postma DS; Paré PD; Ramasamy A; Mägi R; Mihailov E; Reinmaa E; Melén E; O'Connell J; Frangou E; Delaneau O; Freeman C; Petkova D; McCarthy M; Sayers I; Deloukas P; Hubbard R; Pavord I; Hansell AL; Thomson NC; Zeggini E; Morris AP; Marchini J; Strachan DP; Tobin MD; Hall IP; Farrall M; Barroso I; Anderson CA; Botía J; Vandrocova J; Guelfi S; D'Sa K; Ryten M; Trabzuni D; Matarin M; Hardy JA; Weale ME; Varghese V; Forabosco P; Farmer A; McGuffin P; Zgaga L; Wilson JF; Wild SH; Campbell H; Rudan I; Smith C; Walker R; Liu JZ; Tozzi F; Muglia P; Waterworth DM; Pillai SG; Yuan X; Mooser V; Middleton L; Kooner J; Chambers JC; Berrettini W; Knouff CW; Waeber G; Vollenweider P; Preisig M; Wareham NJ; Zhao JH; Loos RJF; Khaw KT; Grundy S; Barter P; Mahley R; Kesaniemi A; McPherson R; Vincent JB; Strauss J; Kennedy JL; Day R; Matthews K; Bakke P; Gulsvik A; Lucae S; Ising M; Brueckl T; Horstmann S; Wichmann HE; Rawal R; Wichmann HE, 2015, 'Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): A genetic association study in UK Biobank', The Lancet Respiratory Medicine, vol. 3, pp. 769 - 781, http://dx.doi.org/10.1016/S2213-2600(15)00283-0
Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA, 2015, 'Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis', International Journal of Cardiology, vol. 199, pp. 204 - 212, http://dx.doi.org/10.1016/j.ijcard.2015.07.014
Ong KL; Januszewski AS; O’Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Rye KA; Keech AC, 2015, 'Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study', Diabetologia, vol. 58, pp. 2035 - 2044, http://dx.doi.org/10.1007/s00125-015-3652-2
Hovingh GK; Kastelein JJP; Van Deventer SJH; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ, 2015, 'Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): A randomised, double-blind, placebo-controlled phase 2 trial', The Lancet, vol. 386, pp. 452 - 460, http://dx.doi.org/10.1016/S0140-6736(15)60158-1
Ong KL; Ding J; McClelland RL; Cheung BMY; Criqui MH; Barter PJ; Rye KA; Allison MA, 2015, 'Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis', Atherosclerosis, vol. 241, pp. 664 - 670, http://dx.doi.org/10.1016/j.atherosclerosis.2015.06.027
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis', Atherosclerosis, vol. 241, pp. 450 - 454, http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.029
Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R, 2015, 'TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)', BMC Cancer, vol. 15, http://dx.doi.org/10.1186/s12885-015-1529-x
Ghersi D; Willson ML; Chan MMK; Simes J; Donoghue E; Wilcken N, 2015, 'Taxane-containing regimens for metastatic breast cancer', Cochrane Database of Systematic Reviews, vol. 2015, http://dx.doi.org/10.1002/14651858.CD003366.pub3
Chantrill LA; Nagrial AM; Watson C; Johns AL; Martyn-Smith M; Simpson S; Mead S; Jones MD; Samra JS; Gill AJ; Watson N; Chin VT; Humphris JL; Chou A; Brown B; Morey A; Pajic M; Grimmond SM; Chang DK; Thomas D; Sebastian L; Sjoquist K; Yip S; Pavlakis N; Asghari R; Harvey S; Grimison P; Simes J; Biankin AV, 2015, 'Precision medicine for advanced pancreas cancer: The individualized molecular pancreatic cancer therapy (IMPaCT) Trial', Clinical Cancer Research, vol. 21, pp. 2029 - 2037, http://dx.doi.org/10.1158/1078-0432.CCR-15-0426
Ong KL; Ding J; McClelland RL; Cheung BMY; Criqui MH; Barter PJ; Rye KA; Allison MA, 2015, 'Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 239, pp. 386 - 392, http://dx.doi.org/10.1016/j.atherosclerosis.2015.01.033
Price TJ; Bruhn MA; Lee CK; Hardingham JE; Townsend AR; Mann KP; Simes J; Weickhardt A; Wrin JW; Wilson K; Gebski V; Van Hazel G; Robinson B; Cunningham D; Tebbutt NC, 2015, 'Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer', British Journal of Cancer, vol. 112, pp. 963 - 970, http://dx.doi.org/10.1038/bjc.2015.37
Borel AL; Nazare JA; Smith J; Aschner P; Barter P; Van Gaal L; Eng Tan C; Wittchen HU; Matsuzawa Y; Kadowaki T; Ross R; Brulle-Wohlhueter C; Alméras N; Haffner SM; Balkau B; Després JP, 2015, 'Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance', International Journal of Obesity, vol. 39, pp. 495 - 501, http://dx.doi.org/10.1038/ijo.2014.163
Ong KL; Januszewski AS; O’Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Scott RS; Taskinen MR; Keech AC; Rye KA, 2015, 'The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study', Diabetologia, vol. 58, pp. 464 - 473, http://dx.doi.org/10.1007/s00125-014-3458-7
Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA, 2015, 'Cholesteryl Ester Transfer Protein Inhibition Enhances Endothelial Repair and Improves Endothelial Function in the Rabbit', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, pp. 628 - 636, http://dx.doi.org/10.1161/ATVBAHA.114.304747
Priglinger M; Arima H; Anderson C; Krause M; Chalmers J; Anderson CS; Huang Y; Wang JG; Arima H; Bath P; Davis S; Kim J; Lindley R; Neal B; Morgenstern LB; MacMahon S; Woodward M; Butcher K; Chambers B; Donnan G; Levi C; Parsons MW; Dorsch N; Huang Y; Wang JG; Lu C; Chen S; Jiang JD; Liu Z; Zhang J; Kong L; Song Y; Wang Z; Wang W; Wu F; Yuan Y; Kim JS; Kim J; Simes J; Hankey G; Jamrozik K; Johnston S; Shunwei L; Skulina C; Peng B; Billot L; Li Q; Su S; Heritier S; Heeley E; Capper H; Chisholm J; Currie R; Fathers J; Hackett M; Homewood S; Jane K; Jones K; Leksuwat S; Mullane B; Pandey S; Patel A; Quilkey A; Scott J; Starzec G; Wadham A; Zeckendorf S; Han D; Ying S; Xu W; Zhang LJ; Huang Q; Li Y; Yan L; Kyung S, 2015, 'No relationship of lipid-lowering agents to hematoma growth: Pooled analysis of the intensive blood pressure reduction in acute cerebral hemorrhage trials studies', Stroke, vol. 46, pp. 857 - 859, http://dx.doi.org/10.1161/STROKEAHA.114.007664
Nazare JA; Smith J; Borel AL; Aschner P; Barter P; Van Gaal L; Tan CE; Wittchen HU; Matsuzawa Y; Kadowaki T; Ross R; Brulle-Wohlhueter C; Alméras N; Haffner SM; Balkau B; Després JP, 2015, 'Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA Study)', American Journal of Cardiology, vol. 115, pp. 307 - 315, http://dx.doi.org/10.1016/j.amjcard.2014.10.039
Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; Sisk CMC; Dansky H; Mitchel Y; Barter P; DEFINE Investigators , 2015, 'Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib) trial', Journal of Clinical Lipidology, vol. 9, pp. 65 - 71, http://dx.doi.org/10.1016/j.jacl.2014.10.005
Barter PJ; Nicholls SJ; Kastelein JJP; Rye KA, 2015, 'Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk?: CETP inhibition as a strategy to reduce cardiovascular risk: The pro case', Circulation, vol. 132, pp. 423 - 432, http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014025
Fulcher J; O'Connell R; Voysey M; Emberson J; Blackwell L; Mihaylova B; Simes J; Collins R; Kirby A; Colhoun H; Braunwald E; La Rosa J; Pedersen TR; Tonkin A; Davis B; Sleight P; Franzosi MG; Baigent C; Keech A; De Lemos J; Blazing M; Murphy S; Downs JR; Gotto A; Clearfield M; Holdaas H; Gordon D; Koren M; Dahlöf B; Poulter N; Sever P; Knopp RH; Fellström B; Jardine A; Schmieder R; Zannad F; Goldbourt U; Kaplinsky E; Betteridge DJ; Durrington PN; Hitman GA; Fuller J; Neil A; Wanner C; Krane V; Sacks F; Moyé L; Pfeffer M; Hawkins CM; Kjekshus J; Wedel H; Wikstrand J; Barter P; Tavazzi L; Maggioni A; Marchioli R; Tognoni G; Bloomfield H; Robins S; Armitage J; Parish S; Peto R; Ridker PM; Holman R; Meade T; MacMahon S; Marschner I; Shaw J; Serruys PW; Nakamura H; Knatterud G; Furberg C; Byington R; Macfarlane P; Cobbe S; Ford I; Murphy M; Marschner IC; Blauw GJ; Packard C; Shepherd J; Wilhelmsen L; Cannon C; Bowman L; Landray M; Rossouw J; Probstfield J; Cobbe S; Flather M; Kastelein J; Newman C; Shear C; Tobert J; Varigos J; White H; Yusuf S; Barnes EH; Herrington WG; Holland LE; Reith C, 2015, 'Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials', The Lancet, vol. 385, pp. 1397 - 1405, http://dx.doi.org/10.1016/S0140-6736(14)61368-4
Sullivan DR; Watts GF; Nicholls SJ; Barter P; Grenfell R; Chow CK; Tonkin A; Keech A, 2015, 'Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review', Heart Lung and Circulation, vol. 24, pp. 495 - 502, http://dx.doi.org/10.1016/j.hlc.2014.12.009
Weickhardt AJ; Williams DS; Lee CK; Chionh F; Simes J; Murone C; Wilson K; Parry MM; Asadi K; Scott AM; Punt CJA; Nagtegaal ID; Price TJ; Mariadason JM; Tebbutt NC, 2015, 'Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer', British Journal of Cancer, vol. 113, pp. 37 - 45, http://dx.doi.org/10.1038/bjc.2015.209
Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJP, 2014, 'Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0114519
Ong KL; McClelland RL; Rye KA; Cheung BMY; Post WS; Vaidya D; Criqui MH; Cushman M; Barter PJ; Allison MA, 2014, 'The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: The multi-ethnic study of atherosclerosis', Atherosclerosis, vol. 236, pp. 257 - 262, http://dx.doi.org/10.1016/j.atherosclerosis.2014.07.015
Cochran BJ; Bisoendial RJ; Hou L; Glaros E; Rossy J; Thomas SR; Barter PJ; Rye KA, 2014, 'Apolipoprotein a-I increases insulin secretion and production from pancreatic β-cells via a g-protein-camp-PKA-FOXO1-dependent mechanism', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 2261 - 2267, http://dx.doi.org/10.1161/ATVBAHA.114.304131
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD, 2014, 'Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects', Journal of the American College of Cardiology, vol. 63, pp. 2365 - 2373, http://dx.doi.org/10.1016/j.jacc.2014.02.538
Mcgrath P; Ghersi D; Simes J; Wilcken N, 2014, 'Larger versus smaller dose of the same drug/s regimen for metastatic breast cancer', Cochrane Database of Systematic Reviews, vol. 2014, http://dx.doi.org/10.1002/14651858.CD003365.pub3
Ong KL; Waters DD; Messig M; Demicco DA; Rye KA; Barter PJ, 2014, 'Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the Treating to New Targets Study)', American Journal of Cardiology, vol. 113, pp. 1593 - 1598, http://dx.doi.org/10.1016/j.amjcard.2014.02.011
Arsenault BJ; Boekholdt SM; Mora S; Demicco DA; Bao W; Tardif JC; Amarenco P; Pedersen T; Barter P; Waters DD, 2014, 'Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)', American Journal of Cardiology, vol. 113, pp. 1378 - 1382, http://dx.doi.org/10.1016/j.amjcard.2014.01.414
Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye KA, 2014, 'The relationship between total Bilirubin levels and total mortality in older adults: The United States national health and nutrition examination survey (NHANES) 1999-2004', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0094479
Barter P, 2014, 'Lipoprotein metabolism and CKD: Overview', Clinical and Experimental Nephrology, vol. 18, pp. 243 - 246, http://dx.doi.org/10.1007/s10157-013-0866-9
Wu BJ; Ong KL; Shrestha S; Chen K; Tabet F; Barter PJ; Rye KA, 2014, 'Inhibition of arthritis in the lewis rat by apolipoprotein A-I and reconstituted high-density lipoproteins', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 543 - 551, http://dx.doi.org/10.1161/ATVBAHA.113.302832
Tabet F; Vickers KC; Cuesta Torres LF; Wiese CB; Shoucri BM; Lambert G; Catherinet C; Prado-Lourenco L; Levin MG; Thacker S; Sethupathy P; Barter PJ; Remaley AT; Rye KA, 2014, 'HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells', Nature Communications, vol. 5, http://dx.doi.org/10.1038/ncomms4292
Grundy SM; Arai H; Barter P; Bersot TP; Betteridge DJ; Carmena R; Cuevas A; Davidson MH; Genest J; Kesäniemi YA; Sadikot S; Santos RD; Susekov A; Sy R; Tokgozoglu L; Watts GF; Zhao D, 2014, 'An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Executive summary.', Atherosclerosis, vol. 232, pp. 410 - 413, http://dx.doi.org/10.1016/j.atherosclerosis.2013.11.031
Rye KA; Barter PJ, 2014, 'Thematic review series: High density lipoprotein structure, function, and metabolism cardioprotective functions of HDLs 1', Journal of Lipid Research, vol. 55, pp. 168 - 179, http://dx.doi.org/10.1194/jlr.R039297
Fruchart JC; Davignon J; Hermans MP; Al-Rubeaan K; Amarenco P; Assmann G; Barter P; Betteridge J; Bruckert E; Cuevas A; Farnier M; Ferrannini E; Fioretto P; Genest J; Ginsberg HN; Gotto AM; Hu D; Kadowaki T; Kodama T; Krempf M; Matsuzawa Y; Núñez-Cortés JM; Monfil CC; Ogawa H; Plutzky J; Rader DJ; Sadikot S; Santos RD; Shlyakhto E; Sritara P; Sy R; Tall A; Tan CE; Tokgözoǧlu L; Toth PP; Valensi P; Wanner C; Zambon A; Zhu J; Zimmet P, 2014, 'Residual macrovascular risk in 2013: What have we learned?', Cardiovascular Diabetology, vol. 13, http://dx.doi.org/10.1186/1475-2840-13-26
Rye KA; Barter PJ, 2014, 'Regulation of high-density lipoprotein metabolism', Circulation Research, vol. 114, pp. 143 - 156, http://dx.doi.org/10.1161/CIRCRESAHA.114.300632
Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P, 2014, 'Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease', American Journal of Cardiology, vol. 113, pp. 76 - 83, http://dx.doi.org/10.1016/j.amjcard.2013.08.041
McGrath KC; Li XH; Whitworth PT; Kasz R; Tan JT; McLennan SV; Celermajer DS; Barter PJ; Rye KA; Heather AK, 2014, 'High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation', Journal of Lipid Research, vol. 55, pp. 421 - 430, http://dx.doi.org/10.1194/jlr.M043281
Ong KL; Barter PJ; Waters DD, 2014, 'Cardiovascular drugs that increase the risk of new-onset diabetes', American Heart Journal, vol. 167, pp. 421 - 428, http://dx.doi.org/10.1016/j.ahj.2013.12.025
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ, 2014, 'Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn', JACC: Cardiovascular Imaging, vol. 7, pp. 1013 - 1022, http://dx.doi.org/10.1016/j.jcmg.2014.04.019
Lim S; Barter P, 2014, 'Antioxidant effects of statins in the management of cardiometabolic disorders', Journal of Atherosclerosis and Thrombosis, vol. 21, pp. 997 - 1010, http://dx.doi.org/10.5551/jat.24398
Stegman B; Puri R; Cho L; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nissen SE; Nicholls SJ, 2014, 'High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: Insights from SATURN', Diabetes Care, vol. 37, pp. 3114 - 3120, http://dx.doi.org/10.2337/dc14-1121
Karlson BW; Toth PP; Palmer MK; Barter PJ; Nicholls SJ, 2014, 'Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER', IJC Metabolic and Endocrine, vol. 5, pp. 61 - 66, http://dx.doi.org/10.1016/j.ijcme.2014.11.002
Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P, 2014, 'Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with Anacetrapib in the DEFINE study', Journal of Cardiovascular Pharmacology and Therapeutics, vol. 19, pp. 543 - 549, http://dx.doi.org/10.1177/1074248414529621
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ, 2014, 'Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: Insights from study of coronary atheroma by intravascular ultrasound: Effect of rosuvastatin versus atorvastatin', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 2465 - 2472, http://dx.doi.org/10.1161/ATVBAHA.114.303932
Simes J; Becattini C; Agnelli G; Eikelboom JW; Kirby AC; Mister R; Prandoni P; Brighton TA, 2014, 'Aspirin for the prevention of recurrent venous thromboembolism the INSPIRE collaboration', Circulation, vol. 130, pp. 1062 - 1071, http://dx.doi.org/10.1161/CIRCULATIONAHA.114.008828
Tardif JC; Ballantyne CM; Barter P; Dasseux JL; Fayad ZA; Guertin MC; Kastelein JJP; Keyserling C; Klepp H; Koenig W; L'Allier PL; Lespérance J; Lüscher TF; Paolini JF; Tawakol A; Waters DD, 2014, 'Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: A randomized trial', European Heart Journal, vol. 35, pp. 3277 - 3286, http://dx.doi.org/10.1093/eurheartj/ehu171
Olsen DA; Hayes JW; Booker DJ; Barter PJ, 2014, 'A Model incorporating disturbance and recovery processes in benthic invertebrate habitat-flow time series', River Research and Applications, vol. 30, pp. 413 - 426, http://dx.doi.org/10.1002/rra.2649
Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ, 2014, 'Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: Insights from SATURN', European Heart Journal Cardiovascular Imaging, vol. 15, pp. 380 - 388, http://dx.doi.org/10.1093/ehjci/jet251
Grundy SM; Arai H; Barter P; Bersot TP; Betteridge DJ; Carmena R; Cuevas A; Davidson MH; Genest J; Kesäniemi YA; Sadikot S; Santos RD; Susekov AV; Sy RG; LaleTokgözoglu S; Watts GF; Zhao D, 2014, 'An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report', Journal of Clinical Lipidology, vol. 8, pp. 29 - 60, http://dx.doi.org/10.1016/j.jacl.2013.12.005
Barter P, 2014, 'International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia', Clinica e Investigacion en Arteriosclerosis, vol. 26, pp. 21 - 22, http://dx.doi.org/10.1016/j.arteri.2013.09.004
White HD; Simes J; Stewart RAH; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM; Nestel P; Keech AC; Sullivan DR; Hunt D; Tonkin A, 2013, 'Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: Results from the long-term intervention with pravastatin in ischemic disease study', Journal of the American Heart Association, vol. 2, pp. 1 - 13, http://dx.doi.org/10.1161/JAHA.113.000360
Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW, 2013, 'Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: An analysis from the VOYAGER database', European Journal of Preventive Cardiology, vol. 20, pp. 1080 - 1087, http://dx.doi.org/10.1177/2047487313489875
Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ, 2013, 'C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy', Circulation, vol. 128, pp. 2395 - 2403, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004243
Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ, 2013, 'Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy', European Heart Journal, vol. 34, pp. 3182 - 3190, http://dx.doi.org/10.1093/eurheartj/eht260
Rosenson RS; Brewer HB; Ansell B; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR, 2013, 'Translation of high-density lipoprotein function into clinical practice: Current prospects and future challenges', Circulation, vol. 128, pp. 1256 - 1267, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.000962
Barter PJ, 2013, 'High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes', ENDOCRINOLOGY AND METABOLISM, vol. 28, pp. 169 - 177, http://dx.doi.org/10.3803/EnM.2013.28.3.169
Toth PP; Barter PJ; Rosenson RS; Boden WE; Chapman MJ; Cuchel M; D'Agostino RB; Davidson MH; Davidson WS; Heinecke JW; Karas RH; Kontush A; Krauss RM; Miller M; Rader DJ, 2013, 'High-density lipoproteins: A consensus statement from the National Lipid Association', Journal of Clinical Lipidology, vol. 7, pp. 484 - 525, http://dx.doi.org/10.1016/j.jacl.2013.08.001
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ, 2013, 'Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 trial', Journal of Clinical Oncology, vol. 31, pp. 2477 - 2484, http://dx.doi.org/10.1200/JCO.2012.46.0543
Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St. John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ, 2013, 'Factors underlying regression of coronary atheroma with potent statin therapy', European Heart Journal, vol. 34, http://dx.doi.org/10.1093/eurheartj/eht084
Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye KA, 2013, 'Trends in C-reactive protein levels in US adults from 1999 to 2010', American Journal of Epidemiology, vol. 177, pp. 1430 - 1442, http://dx.doi.org/10.1093/aje/kws443
Chapman MJ; Giral P; Barter PJ, 2013, 'The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: Insight from EPIC-Norfolk and JUPITER', European Heart Journal, vol. 34, pp. 1318 - 1320, http://dx.doi.org/10.1093/eurheartj/eht074
Karlson BW; Nicholls SJ; Lundman P; Palmer MK; Barter PJ, 2013, 'Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER', Atherosclerosis, vol. 228, pp. 265 - 269, http://dx.doi.org/10.1016/j.atherosclerosis.2013.02.027
Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ; Kastelein JJP; Lambert G, 2013, 'Erratum: Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) Trial (Journal of the American College of Cardiology (2012) 59 (1778-1784))', Journal of the American College of Cardiology, vol. 61, pp. 1751, http://dx.doi.org/10.1016/j.jacc.2013.04.002
Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJP, 2013, 'Erratum: Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Journal of the American College of Cardiology (2011) 57 (63-69))', Journal of the American College of Cardiology, vol. 61, pp. 1750, http://dx.doi.org/10.1016/j.jacc.2013.03.006
Schwartz GG; Olsson AG; Barter PJ, 2013, 'Dalcetrapib in patients with an acute coronary syndrome.', The New England journal of medicine, vol. 368, pp. 869 - 870, http://dx.doi.org/10.1056/NEJMc1300057
Davidson M; Liu SX; Barter P; Brinton EA; Cannon CP; Gotto AM; Leary ET; Shah S; Stepanavage M; Mitchel Y; Dansky HM, 2013, 'Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib', Journal of Lipid Research, vol. 54, pp. 467 - 472, http://dx.doi.org/10.1194/jlr.M032615
Wu BJ; Chen K; Shrestha S; Ong KL; Barter PJ; Rye KA, 2013, 'High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-[INCREMENT]24 reductase expression and inducing heme oxygenase-1', Circulation Research, vol. 112, pp. 278 - 288, http://dx.doi.org/10.1161/CIRCRESAHA.111.300104
Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye KA, 2013, 'Arthritis: Its prevalence, Risk factors, And association with cardiovascular diseases in the United States, 1999 to 2008', Annals of Epidemiology, vol. 23, pp. 80 - 86, http://dx.doi.org/10.1016/j.annepidem.2012.11.008
Thorgeirsson TE; Gudbjartsson DF; Sulem P; Besenbacher S; Styrkarsdottir U; Thorleifsson G; Walters GB; Furberg H; Sullivan PF; Marchini J; McCarthy MI; Steinthorsdottir V; Thorsteinsdottir U; Stefansson K; Surakka I; Vink JM; Amin N; Geller F; Rafnar T; Esko T; Walter S; Gieger C; Rawal R; Mangino M; Prokopenko I; Mägi R; Keskitalo K; Gudjonsdottir IH; Gretarsdottir S; Stefansson H; Aulchenko YS; Nelis M; Aben KK; Den Heijer M; Soranzo N; Valdes AM; Steves C; Uitterlinden AG; Hofman A; Tönjes A; Kovacs P; Hottenga JJ; Willemsen G; Vogelzangs N; Döring A; Dahmen N; Nitz B; Ripatti S; Perola M; Kettunen J; Hartikainen AL; Pouta A; Laitinen J; Isohanni M; Huei-Yi S; Allen M; Krestyaninova M; Hall AS; Thompson JR; Oskarsson H; Tyrfingsson T; Kiemeney LA; Järvelin MR; Salomaa V; Stumvoll M; Spector TD; Wichmann HE; Metspalu A; Samani NJ; Penninx BW; Oostra BA; Boomsma DI; Tiemeier H; Van Duijn CM; Kaprio J; Gulcher JR; Kim YJ; Dackor J; Boerwinkle E; Franceschini N; Ardissino D; Bernardinelli L; Mannucci PM; Mauri F; Merlini PA; Absher D; Assimes TL; Fortmann SP; Iribarren C; Knowles JW; Quertermous T; Ferrucci L; Tanaka T; Bis JC; Furberg CD; Haritunians T; McKnight B; Psaty BM; Taylor KD; Thacker EL, 2013, 'A common biological basis of obesity and nicotine addiction', Translational Psychiatry, vol. 3, pp. 1 - 7, http://dx.doi.org/10.1038/tp.2013.81
Smith J; Nazare JA; Borel AL; Aschner P; Barter PJ; Van Gaal L; Matsuzawa Y; Kadowaki T; Ross R; Brulle-Wohlhueter C; Alméras N; Haffner SM; Balkau B; Després JP, 2013, 'Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: Results from INSPIRE ME IAA', Diabetes, Obesity and Metabolism, vol. 15, pp. 629 - 641, http://dx.doi.org/10.1111/dom.12075
Morales-Villegas E; Moreno-Virgen G; Barter PJ, 2012, 'CETP pharmacological manipulation transforming human into mouse: Is this still a viable hypothesis?', Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, vol. 12, pp. 266 - 278, http://dx.doi.org/10.2174/187152212803521057
Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC, 2012, 'Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 97, pp. 4701 - 4708, http://dx.doi.org/10.1210/jc.2012-2267
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS, 2012, 'Effects of dalcetrapib in patients with a recent acute coronary syndrome', New England Journal of Medicine, vol. 367, pp. 2089 - 2099, http://dx.doi.org/10.1056/NEJMoa1206797
Barter PJ; Rye KA; Beltangady MS; Ports WC; Duggan WT; Boekholdt SM; DeMicco DA; Kastelein JJP; Shear CL, 2012, 'Relationship between atorvastatin dose and the harm caused by torcetrapib', Journal of Lipid Research, vol. 53, pp. 2436 - 2442, http://dx.doi.org/10.1194/jlr.P026328
Barter PJ; Rye KA, 2012, 'Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk', Journal of Lipid Research, vol. 53, pp. 1755 - 1766, http://dx.doi.org/10.1194/jlr.R024075
Karlson BW; Barter PJ; Palmer MK; Lundman P; Nicholls SJ, 2012, 'Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER', Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, pp. 697 - 703, http://dx.doi.org/10.1016/j.numecd.2012.03.003
Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C; De Lemos J; Braunwald E; Blazing M; Murphy S; Downs JR; Gotto A; Clearfield M; Holdaas H; Gordon D; Davis B; Koren M; Dahlof B; Poulter N; Sever P; Knopp RH; Fellstrom B; Jardine A; Schmieder R; Zannad F; Goldbourt U; Kaplinsky E; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Fuller J; Neil A; Wanner C; Krane V; Sacks F; Moye L; Pfeffer M; Hawkins CM; Kjekshus J; Wedel H; Wikstrand J; Barter P; Tavazzi L; Maggioni A; Marchioli R; Tognoni G; Franzosi MG; Bloomfield H; Robins S; Armitage J; Parish S; Peto R; Sleight P; Pedersen TR; Ridker PM; Holman R; Meade T; MacMahon S; Marschner I; Tonkin A; Shaw J; Serruys PW; Nakamura H; Knatterud G; Marschner I; Byington R; MacFarlane P; Cobbe S; Ford I; Murphy M; Blauw GJ; Packard C; Shepherd J; Wilhelmsen L; Cannon C; Bowman L; Landray M; La Rosa J; Rossouw J; Probstfi Eld J; Flather M; Kastelein J; Newman C; Shear C; Tobert J; Varigos J; White H; Yusuf S; Mellies M; McGovern M; Barclay J; Belder R; Mitchel MY; Musliner T; Ansquer JC, 2012, 'The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials', The Lancet, vol. 380, pp. 581 - 590, http://dx.doi.org/10.1016/S0140-6736(12)60367-5
Rye KA; Barter PJ, 2012, 'The inhibition of cholesteryl ester transfer protein: A long and winding road', Journal of Lipid Research, vol. 53, pp. 1039 - 1041, http://dx.doi.org/10.1194/jlr.E027334
Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; Demicco DA; Barter PJ; Kastelein JJP; Lambert G, 2012, 'Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: A nested case-control study', Journal of the American College of Cardiology, vol. 59, pp. 1778 - 1784, http://dx.doi.org/10.1016/j.jacc.2011.12.043
Tso C; Rye KA; Barter P, 2012, 'Phenotypic and functional changes in blood monocytes following adherence to endothelium', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0037091
Drew BG; Rye KA; Duffy SJ; Barter P; Kingwell BA, 2012, 'The emerging role of HDL in glucose metabolism', Nature Reviews Endocrinology, vol. 8, pp. 237 - 245, http://dx.doi.org/10.1038/nrendo.2011.235
Nicholls SJ; Gordon A; Johannson J; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Wong NC; Borgman MRN; Nissen SE, 2012, 'ApoA-I induction as a potential cardioprotective strategy: Rationale for the SUSTAIN and ASSURE studies', Cardiovascular Drugs and Therapy, vol. 26, pp. 181 - 187, http://dx.doi.org/10.1007/s10557-012-6373-5
Dastani Z; Hivert MF; Timpson N; Perry JRB; Yuan X; Scott RA; Henneman P; Heid IM; Kizer JR; Lyytikäinen LP; Fuchsberger C; Tanaka T; Morris AP; Small K; Isaacs A; Beekman M; Coassin S; Lohman K; Qi L; Kanoni S; Pankow JS; Uh HW; Wu Y; Bidulescu A; Rasmussen-Torvik LJ; Greenwood CMT; Ladouceur M; Grimsby J; Manning AK; Liu CT; Kooner J; Mooser VE; Vollenweider P; Kapur KA; Chambers J; Wareham NJ; Langenberg C; Frants R; Willems-VanDijk K; Oostra BA; Willems SM; Lamina C; Winkler TW; Psaty BM; Tracy RP; Brody J; Chen I; Viikari J; Kähönen M; Pramstaller PP; Evans DM; St. Pourcain B; Sattar N; Wood AR; Bandinelli S; Carlson OD; Egan JM; Böhringer S; van Heemst D; Kedenko L; Kristiansson K; Nuotio ML; Loo BM; Harris T; Garcia M; Kanaya A; Haun M; Klopp N; Wichmann HE; Deloukas P; Katsareli E; Couper DJ; Duncan BB; Kloppenburg M; Adair LS; Borja JB; Florez JC; MAGIC Consortium ; GLGC Investigators ; MuTHER Consortium ; Wilson JG; Musani S; Guo X; Johnson T; Semple R; Teslovich TM; Redline S; Buxbaum SG; Mohlke KL; Meulenbelt I; Ballantyne CM; Dedoussis GV; Hu FB; Liu Y; Paulweber B; Spector TD; Slagboom PE; Ferrucci L; Jula A; Perola M, 2012, 'Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multi-ethnic meta-analysis of 45,891 individuals', PLoS Genetics, vol. 8, http://dx.doi.org/10.1371/journal.pgen.1002607
Rye KA; Barter PJ, 2012, 'Predictive value of different HDL particles for the protection against or risk of coronary heart disease', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1821, pp. 473 - 480, http://dx.doi.org/10.1016/j.bbalip.2011.10.012
Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJP, 2012, 'The 719Arg variant of kIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies', Circulation: Cardiovascular Genetics, vol. 5, pp. 51 - 57, http://dx.doi.org/10.1161/CIRCGENETICS.111.960252
Emberson JR; Kearney PM; Blackwell L; Newman C; Reith C; Bhala N; Holland L; Peto R; Keech A; Collins R; Simes J; Baigent C; De Lemos J; Braunwald E; Blazing M; Murphy S; Downs JR; Gotto A; Clearfield M; Holdaas H; Gordon D; Davis B; Koren M; Dahlof B; Poulter N; Sever P; Knopp RH; Fellström B; Jardine A; Schmieder R; Zannad F; Goldbourt U; Kaplinsky E; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Fuller J; Neil A; Wanner C; Krane V; Sacks F; Moyé L; Pfeffer M; Hawkins CM; Kjekshus J; Wedel H; Wikstrand J; Tavazzi L; Maggioni A; Marchioli R; Tognoni G; Franzosi MG; Armitage J; Parish S; Sleight P; Pedersen TR; Ridker PM; MacMahon S; Marschner I; Tonkin A; Shaw J; Serruys PW; Nakamura H; Knatterud G; Furberg C; Byington R; Macfarlane P; Cobbe S; Ford I; Murphy M; Blauw GJ; Packard C; Shepherd J; Wilhelmsen L; Cannon C; Bowman L; La Rosa J; Flather M; Kastelein J; Shear C; Tobert J; Varigos J; White H; Yusuf S; Baxter A; Barnes EH; Buck G; Herrington WG; Kirby A; Lewis DA; Mellies M; McGovern M; Barclay J; Belder R; Mitchell Y; Musliner T; Ansquer JC; Llewellyn M; Bortolini M, 2012, 'Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0029849
Wu BJ; Chen K; Barter PJ; Rye KA, 2012, 'Niacin inhibits vascular inflammation via the induction of heme oxygenase-1', Circulation, vol. 125, pp. 150 - 158, http://dx.doi.org/10.1161/CIRCULATIONAHA.111.053108
Dear RF; Barratt AL; Evans A; Simes J; Newsom J; Kent D; Crossing S; Holliday C; Segelov E; Hruby G; Tattersall MHN, 2012, 'Identifying and prioritising gaps in colorectal cancer trials research in Australia', Medical Journal of Australia, vol. 197, pp. 507 - 511, http://dx.doi.org/10.5694/mja12.10623
Ong KL; Barter PJ; Rye KA, 2011, 'Response to statin use and serum bilirubin levels', Atherosclerosis, vol. 219, pp. 392, http://dx.doi.org/10.1016/j.atherosclerosis.2011.09.007
Di Bartolo BA; Vanags LZ; Tan JT; Bao S; Rye KA; Barter PJ; Bursill CA, 2011, 'The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.', Lipids in health and disease, vol. 10, pp. 224, http://dx.doi.org/10.1186/1476-511X-10-224
Barter P; Rye KA, 2011, 'Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?', Trends in Pharmacological Sciences, vol. 32, pp. 694 - 699, http://dx.doi.org/10.1016/j.tips.2011.07.004
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE, 2011, 'Effect of two intensive statin regimens on progression of coronary disease', New England Journal of Medicine, vol. 365, pp. 2078 - 2087, http://dx.doi.org/10.1056/NEJMoa1110874
Barter P, 2011, 'Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction.', Atherosclerosis. Supplements, vol. 12, pp. 265 - 266
Barter P, 2011, 'HDL-C: Role as a risk modifier', Atherosclerosis Supplements, vol. 12, pp. 267 - 270, http://dx.doi.org/10.1016/S1567-5688(11)70885-6
Watts GF; Sullivan DR; Poplawski N; van Bockxmeer F; Hamilton-Craig I; Clifton PM; O'Brien R; Bishop W; George P; Barter PJ; Bates T; Burnett JR; Coakley J; Davidson P; Emery J; Martin A; Farid W; Freeman L; Geelhoed E; Juniper A; Kidd A; Kostner K; Krass I; Livingston M; Maxwell S; O'Leary P; Owaimrin A; Redgrave TG; Reid N; Southwell L; Suthers G; Tonkin A; Towler S; Trent R, 2011, 'Familial hypercholesterolaemia: A model of care for Australasia', Atherosclerosis Supplements, vol. 12, pp. 221 - 263, http://dx.doi.org/10.1016/j.atherosclerosissup.2011.06.001
Chan JCN; Chan SP; Deerochanawong C; Go RT; Lee KO; Ma RCW; Pan CY; Sheu WHH; Barter P, 2011, 'Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know', Diabetes Research and Clinical Practice, vol. 94, pp. 1 - 13, http://dx.doi.org/10.1016/j.diabres.2011.05.034
Barter PJ; Rye KA; Tardif JC; Waters DD; Matthijs BS; Breazna A; Kastelein JJP, 2011, 'Effect of torcetrapib on glucose, insulin, and hemoglobin a1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (Illuminate) Trial', Circulation, vol. 124, pp. 555 - 562, http://dx.doi.org/10.1161/CIRCULATIONAHA.111.018259
Di Bartolo BA; Nicholls SJ; Bao S; Rye KA; Heather AK; Barter PJ; Bursill C, 2011, 'The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins', Atherosclerosis, vol. 217, pp. 395 - 400, http://dx.doi.org/10.1016/j.atherosclerosis.2011.04.001
Reimers GJ; Jackson CL; Rickards J; Chan PY; Cohn JS; Rye KA; Barter PJ; Rodgers KJ, 2011, 'Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I', Cardiovascular Research, vol. 91, pp. 37 - 44, http://dx.doi.org/10.1093/cvr/cvr057
Preiss D; Seshasai SRK; Welsh P; Murphy SA; Ho JE; Waters DD; DeMicco DA; Barter P; Cannon CP; Sabatine MS; Braunwald E; Kastelein JJP; De Lemos JA; Blazing MA; Pedersen TR; Tikkanen MJ; Sattar N; Ray KK, 2011, 'Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis', JAMA - Journal of the American Medical Association, vol. 305, pp. 2556 - 2564, http://dx.doi.org/10.1001/jama.2011.860
Nicholls SJ; Borgman M; Nissen SE; Raichlen JS; Ballantyne C; Barter P; Chapman MJ; Erbel R; Libby P, 2011, 'Impact of statins on progression of atherosclerosis: Rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN)', Current Medical Research and Opinion, vol. 27, pp. 1119 - 1129, http://dx.doi.org/10.1185/03007995.2011.570746
Tabet F; Lambert G; Cuesta Torres LF; Hou L; Sotirchos I; Touyz RM; Jenkins AJ; Barter PJ; Rye KA, 2011, 'Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, pp. 1192 - 1200, http://dx.doi.org/10.1161/ATVBAHA.110.222000
Waters DD; Ho JE; DeMicco DA; Breazna A; Arsenault BJ; Wun CC; Kastelein JJ; Colhoun H; Barter P, 2011, 'Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials', Journal of the American College of Cardiology, vol. 57, pp. 1535 - 1545, http://dx.doi.org/10.1016/j.jacc.2010.10.047
Barter PJ, 2011, 'The causes and consequences of low levels of high density lipoproteins in patients with diabetes', Diabetes and Metabolism Journal, vol. 35, pp. 101 - 106, http://dx.doi.org/10.4093/dmj.2011.35.2.101
Speliotes EK; Yerges-Armstrong LM; Wu J; Hernaez R; Kim LJ; Palmer CD; Gudnason V; Eiriksdottir G; Garcia ME; Launer LJ; Nalls MA; Clark JM; Mitchell BD; Shuldiner AR; Butler JL; Tomas M; Hoffmann U; Hwang SJ; Massaro JM; O'Donnell CJ; Sahani DV; Salomaa V; Schadt EE; Schwartz SM; Siscovick DS; Voight BF; Jeffrey Carr J; Feitosa MF; Harris TB; Fox CS; Smith AV; Linda Kao WH; Hirschhorn JN; Borecki IB; McCullough A; Bringman D; Dasarathy S; Edwards K; Hawkins C; Liu YC; Rogers N; Ruth Sargent PAC; Stager M; Diehl AM; Abdelmalek M; Gottfried M; Guy C; Killenberg P; Kwan S; Pan YP; Piercy D; Smith M; Chalasani N; Bhimalli P; Cummings OW; Klipsch A; Lee L; Molleston J; Ragozzino L; Vuppalanchi R; Neuschwander-Tetri BA; Barlow S; Derdoy J; Hoffmann J; King D; Siegner J; Stewart S; Thompson J; Brunt E; Lavine JE; Behling C; Clark L; Durelle J; Hassanein T; Petcharaporn L; Schwimmer JB; Sirlin C; Stein T; Bass NM; Bambha K; Ferrell LD; Filipowski D; Merriman R; Pabst M; Rosenthal M; Rosenthal P; Steel T; Sanyal AJ; Boyett S; Bryan D; Contos MJ; Fuchs M; Graham M; Jones A; Luketic VAC; Sandhu B; Sargeant C; Selph K; White M; Kowdley KV, 2011, 'Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits', PLoS Genetics, vol. 7, http://dx.doi.org/10.1371/journal.pgen.1001324
Arsenault BJ; Barter P; Demicco DA; Bao W; Preston GM; Larosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJP, 2011, 'Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers', Journal of the American College of Cardiology, vol. 57, pp. 63 - 69, http://dx.doi.org/10.1016/j.jacc.2010.06.052
Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye KA, 2011, 'Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008', Atherosclerosis, vol. 219, pp. 728 - 733, http://dx.doi.org/10.1016/j.atherosclerosis.2011.07.094
Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P, 2010, 'Safety of anacetrapib in patients with or at high risk for coronary heart disease', New England Journal of Medicine, vol. 363, pp. 2406 - 2415, http://dx.doi.org/10.1056/NEJMoa1009744
Baigent C; Blackwell L; Emberson J; Holland LE; Reith C; Bhala N; Peto R; Barnes EH; Keech A; Simes J; Collins R; De Lemos J; Braunwald E; Blazing M; Murphy S; Downs JR; Gotto A; Clearfield M; Holdaas H; Gordon D; Davis B; Koren M; Dahlof B; Poulter N; Sever P; Knopp RH; Fellström B; Jardine A; Schmieder R; Zannad F; Goldbourt U; Kaplinsky E; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Fuller J; Neil A; Wanner C; Krane V; Sacks F; Moyé L; Pfeffer M; Hawkins CM; Barter P; Tavazzi L; Maggioni A; Marchioli R; Tognoni G; Franzosi MG; Bloomfield H; Robins S; Armitage J; Parish S; Sleight P; Pedersen TR; Ridker PM; Holman R; Meade T; MacMahon S; Marschner I; Tonkin A; Shaw J; Serruys PW; Nakamura H; Knatterud G; Furberg C; Byington R; Macfarlane P; Cobbe S; Ford I; Murphy M; Blauw GJ; Packard C; Shepherd J; Kjekshus J; Wilhelmsen L; Cannon C; Bowman L; Baxter A; Landray M; La Rosa J; Rossouw J; Probstfield J; Flather M; Kastelein J; Newman C; Shear C; Tobert J; Varigos J; White H; Yusuf S; Mellies M; McGovern M; Barclay J; Belder R; Mitchel Y; Musliner T; Ansquer JC; Llewellyn M, 2010, 'Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials', The Lancet, vol. 376, pp. 1670 - 1681, http://dx.doi.org/10.1016/S0140-6736(10)61350-5
Waterworth DM; Ricketts SL; Song K; Chen L; Zhao JH; Ripatti S; Aulchenko YS; Zhang W; Yuan X; Lim N; Luan J; Ashford S; Wheeler E; Young EH; Hadley D; Thompson JR; Braund PS; Johnson T; Struchalin M; Surakka I; Luben R; Khaw KT; Rodwell SA; Loos RJF; Boekholdt SM; Inouye M; Deloukas P; Elliott P; Schlessinger D; Sanna S; Scuteri A; Jackson A; Mohlke KL; Tuomilehto J; Roberts R; Stewart A; Kesäniemi YA; Mahley RW; Grundy SM; McArdle W; Cardon L; Waeber G; Vollenweider P; Chambers JC; Boehnke M; Abecasis GR; Salomaa V; Järvelin MR; Ruokonen A; Barroso I; Epstein SE; Hakonarson HH; Rader DJ; Reilly MP; Witteman JCM; Hall AS; Samani NJ; Strachan DP; Barter P; Van Duijn CM; Kooner JS; Peltonen L; Wareham NJ; McPherson R; Mooser V; Sandhu MS, 2010, 'Genetic variants influencing circulating lipid levels and risk of coronary artery disease', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 2264 - 2276, http://dx.doi.org/10.1161/ATVBAHA.109.201020
Barter PJ, 2010, 'Point: The relationship between cholesteryl ester transfer protein and cardiovascular risk', Clinical Chemistry, vol. 56, pp. 1547 - 1549, http://dx.doi.org/10.1373/clinchem.2010.150565
Bursill CA; Castro ML; Beattie DT; Nakhla S; Van Der Vorst E; Heather AK; Barter PJ; Rye KA, 2010, 'High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 1773 - 1778, http://dx.doi.org/10.1161/ATVBAHA.110.211342
Taskinen MR; Barter PJ; Ehnholm C; Sullivan DR; Mann K; Simes J; Best JD; Hamwood S; Keech AC, 2010, 'Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes', Diabetologia, vol. 53, pp. 1846 - 1855, http://dx.doi.org/10.1007/s00125-010-1806-9
Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ; Price T; Coates A; O'Connell D; Brown C; Hague W; France A; Hicks S; James R; Masson R; O'Connell R; Pike R; Shoulder J; Stevens L; Tunney V; Vachan B; Wong N; Ackland S; Moylan E; Strickland A; Abdi E; Ransom D; Lowenthal R; Marx G; Nayagam SS; Shannon J; Goldstein D; Karapetis C; Blum R; Eek R; Ward R; Pavlakis N; Wilcken N; Burns I; Wyld D; Underhill C; Claringbold P; Liauw W; Clingan P; Jefford M; Horvath L; McKendrick J; Chong G; Boyce A; Cassidy J; Kirsten F; Clarke S; Guo Y; Innes-Rowe J; Smith A; Williams J; Tournier E; Maliepaard S; Vitullo E; Humm G; Nguyen V; Midolo P; Chorlton C; McDonald L; Oliver L; Sjursen AM; Inglis C; Marafioti T; McCourt J; Howard J; Richards A; Provis A; Rundle A; Whatman A; Emmett L; Raymond B; Byrne S; Withers E; Campbell J; Hodgkins C; Szwajcer M; Parker S; Welby S; Page F; Corker M; Wykes R; Goss C; Whitney S, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, vol. 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723
Barter PJ; Brandrup-Wognsen G; Palmer MK; Nicholls SJ, 2010, 'Effect of statins on HDL-C: A complex process unrelated to changes in LDL-C: Analysis of the VOYAGER database', Journal of Lipid Research, vol. 51, pp. 1546 - 1553, http://dx.doi.org/10.1194/jlr.P002816
Wu BJ; Yan L; Charlton F; Witting P; Barter PJ; Rye KA, 2010, 'Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 968 - 975, http://dx.doi.org/10.1161/ATVBAHA.109.201129
Liu JZ; Tozzi F; Waterworth DM; Pillai SG; Muglia P; Middleton L; Berrettini W; Knouff CW; Yuan X; Waeber G; Vollenweider P; Preisig M; Wareham NJ; Zhao JH; Loos RJF; Barroso I; Khaw KT; Grundy S; Barter P; Mahley R; Kesaniemi A; McPherson R; Vincent JB; Strauss J; Kennedy JL; Farmer A; McGuffin P; Day R; Matthews K; Bakke P; Gulsvik A; Lucae S; Ising M; Brueckl T; Horstmann S; Wichmann HE; Rawal R; Dahmen N; Lamina C; Polasek O; Zgaga L; Huffman J; Campbell S; Kooner J; Chambers JC; Burnett MS; Devaney JM; Pichard AD; Kent KM; Satler L; Lindsay JM; Waksman R; Epstein S; Wilson JF; Wild SH; Campbell H; Vitart V; Reilly MP; Li M; Qu L; Wilensky R; Matthai W; Hakonarson HH; Rader DJ; Franke A; Wittig M; Schäfer A; Uda M; Terracciano A; Xiao X; Busonero F; Scheet P; Schlessinger D; Clair DS; Rujescu D; Abecasis GR; Grabe HJ; Teumer A; Völzke H; Petersmann A; John U; Rudan I; Hayward C; Wright AF; Kolcic I; Wright BJ; Thompson JR; Balmforth AJ; Hall AS; Samani NJ; Anderson CA; Ahmad T; Mathew CG; Parkes M; Satsangi J; Caulfield M; Munroe PB; Farrall M; Dominiczak A; Worthington J, 2010, 'Meta-analysis and imputation refines the association of 15q25 with smoking quantity', Nature Genetics, vol. 42, pp. 436 - 440, http://dx.doi.org/10.1038/ng.572
Dupuis J; Langenberg C; Prokopenko I; Saxena R; Soranzo N; Jackson AU; Wheeler E; Glazer NL; Bouatia-Naji N; Gloyn AL; Lindgren CM; Mägi R; Morris AP; Randall J; Johnson T; Elliott P; Rybin D; Thorleifsson G; Steinthorsdottir V; Henneman P; Grallert H; Dehghan A; Hottenga JJ; Franklin CS; Navarro P; Song K; Goel A; Perry JRB; Egan JM; Lajunen T; Grarup N; Sparsø T; Doney A; Voight BF; Stringham HM; Li M; Kanoni S; Shrader P; Cavalcanti-Proença C; Kumari M; Qi L; Timpson NJ; Gieger C; Zabena C; Rocheleau G; Ingelsson E; An P; O'Connell J; Luan J; Elliott A; McCarroll SA; Payne F; Roccasecca RM; Pattou F; Sethupathy P; Ardlie K; Ariyurek Y; Balkau B; Barter P; Beilby JP; Ben-Shlomo Y; Benediktsson R; Bennett AJ; Bergmann S; Bochud M; Boerwinkle E; Bonnefond A; Bonnycastle LL; Borch-Johnsen K; Böttcher Y; Brunner E; Bumpstead SJ; Charpentier G; Chen YDI; Chines P; Clarke R; Coin LJM; Cooper MN; Cornelis M; Crawford G; Crisponi L; Day INM; De Geus EJC; Delplanque J; Dina C; Erdos MR; Fedson AC; Fischer-Rosinsky A; Forouhi NG; Fox CS; Frants R; Franzosi MG; Galan P; Goodarzi MO; Graessler J; Groves CJ; Grundy S; Gwilliam R; Gyllensten U; Hadjadj S, 2010, 'Erratum: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (Nature Genetics (2010) 42 (105-116))', Nature Genetics, vol. 42, pp. 464, http://dx.doi.org/10.1038/ng0510-464a
Nobécourt E; Tabet F; Lambert G; Puranik R; Bao S; Yan L; Davies MJ; Brown BE; Jenkins AJ; Dusting GJ; Bonnet DJ; Curtiss LK; Barter PJ; Rye KA, 2010, 'Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 766 - 772, http://dx.doi.org/10.1161/ATVBAHA.109.201715
Laurila PP; Naukkarinen J; Kristiansson K; Ripatti S; Kauttu T; Silander K; Salomaa V; Perola M; Karhunen PJ; Barter PJ; Ehnholm C; Peltonen L, 2010, 'Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 346 - 352, http://dx.doi.org/10.1161/ATVBAHA.109.188912
Tabet F; Remaley AT; Segaliny AI; Millet J; Yan L; Nakhla S; Barter PJ; Rye KA; Lambert G, 2010, 'The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 246 - 252, http://dx.doi.org/10.1161/ATVBAHA.109.200196
Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ, 2010, 'Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)', American Journal of Cardiology, vol. 105, pp. 69 - 76, http://dx.doi.org/10.1016/j.amjcard.2009.08.651
Dupuis J; Langenberg C; Prokopenko I; Saxena R; Soranzo N; Jackson AU; Wheeler E; Glazer NL; Bouatia-Naji N; Gloyn AL; Lindgren CM; Mägi R; Morris AP; Randall J; Johnson T; Elliott P; Rybin D; Thorleifsson G; Steinthorsdottir V; Henneman P; Grallert H; Dehghan A; JanHottenga J; Franklin CS; Navarro P; Song K; Goel A; Perry JRB; Egan JM; Lajunen T; Grarup N; Sparsø T; Doney A; Voight BF; Stringham HM; Li M; Kanoni S; Shrader P; Cavalcanti-Proença C; Kumari M; Qi L; Timpson NJ; Gieger C; Zabena C; Rocheleau G; Ingelsson E; An P; O'Connell J; Luan J; Elliott A; McCarroll SA; Payne F; Roccasecca RM; Pattou F; Sethupathy P; Ardlie K; Ariyurek Y; Balkau B; Barter P; Beilby JP; Ben-Shlomo Y; Benediktsson R; Bennett AJ; Bergmann S; Bochud M; Boerwinkle E; Bonnefond A; Bonnycastle LL; Borch-Johnsen K; Böttcher Y; Brunner E; Bumpstead SJ; Charpentier G; Der IdaChen Y; Chines P; Clarke R; McOin LJ; Cooper MN; Cornelis M; Crawford G; Crisponi L; Day INM; De Geus EJC; Delplanque J; Dina C; Erdos MR; Fedson AC; Fischer-Rosinsky A; Forouhi NG; Fox CS; Frants R; GraziaFranzosi M; Galan P; Goodarzi MO; Graessler J; Groves CJ; Grundy S; Gwilliam R; Gyllensten U; Hadjadj S, 2010, 'New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk', Nature Genetics, vol. 42, pp. 105 - 116, http://dx.doi.org/10.1038/ng.520
Patel S; Di bartolo B; Nakhla S; Heather A; Mitchell T; Jessup W; Celermajer D; Barter P; Rye K, 2010, 'Anti-inflammatory effects of apolipoprotein A-I in the rabbit', Atherosclerosis, vol. 212, pp. 392 - 397, http://dx.doi.org/10.1016/j.atherosclerosis.2010.05.035
Fryirs MA; Barter P; Appavoo M; Tuch BE; Tabet F; Heather AK; Rye K, 2010, 'Effects of High-Density Lipoproteins on Pancreatic -Cell Insulin Secretion', Arteriosclerosis, Thrombosis and Vascular Biology, vol. 30, pp. 1642 - 1648, http://dx.doi.org/10.1161/ATVBAHA.110.207373
Brent Richards J; Waterworth D; O'Rahilly S; Hivert MF; Loos RJF; Perry JRB; Tanaka T; Timpson NJ; Semple RK; Soranzo N; Song K; Rocha N; Grundberg E; Dupuis J; Florez JC; Langenberg C; Prokopenko I; Saxena R; Sladek R; Aulchenko Y; Evans D; Waeber G; Erdmann J; Burnett MS; Sattar N; Devaney J; Willenborg C; Hingorani A; Witteman JCM; Vollenweider P; Glaser B; Hengstenberg C; Ferrucci L; Melzer D; Stark K; Deanfield J; Winogradow J; Grassl M; Hall AS; Egan JM; Thompson JR; Ricketts SL; König IR; Reinhard W; Grundy S; Wichmann HE; Barter P; Mahley R; Kesaniemi YA; Rader DJ; Reilly MP; Epstein SE; Stewart AFR; Van Duijn CM; Schunkert H; Burling K; Deloukas P; Pastinen T; Samani NJ; McPherson R; Smith GD; Frayling TM; Wareham NJ; Meigs JB; Mooser V; Spector TD, 2009, 'A genome-wide association study reveals variants in ARL15 that influence adiponectin levels', PLoS Genetics, vol. 5, http://dx.doi.org/10.1371/journal.pgen.1000768
Barter P, 2009, 'Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial', American Journal of Cardiology, vol. 104, pp. 10E - 15E, http://dx.doi.org/10.1016/j.amjcard.2009.09.014
Barter P; MacDonald I, 2009, 'Australia's Heart Research Institute: A remarkable institution in the Southern Hemisphere', European Heart Journal, vol. 30, pp. 2548 - 2550, http://dx.doi.org/10.1093/eurheartj/ehp393
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J, 2009, 'Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels', Archives of Internal Medicine, vol. 169, pp. 1775 - 1780, http://dx.doi.org/10.1001/archinternmed.2009.328
Peshavariya H; Dusting GJ; Di Bartolo B; Rye KA; Barter PJ; Jiang F, 2009, 'Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts', Free Radical Research, vol. 43, pp. 772 - 782, http://dx.doi.org/10.1080/10715760903045304
McGrath KCY; Li XH; Puranik R; Liong EC; Tan JTM; Dy VM; Dibartolo BA; Barter PJ; Rye KA; Heather AK, 2009, 'Role of 3β-hydroxysteroid-Δ24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, pp. 877 - 882, http://dx.doi.org/10.1161/ATVBAHA.109.184663
Fryirs M; Barter PJ; Rye KA, 2009, 'Cholesterol metabolism and pancreatic β-cell function', Current Opinion in Lipidology, vol. 20, pp. 159 - 164, http://dx.doi.org/10.1097/MOL.0b013e32832ac180
Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ, 2009, 'Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, pp. 950 - 955, http://dx.doi.org/10.1161/ATVBAHA.108.178228
Rye KA; Bursill CA; Lambert G; Tabet F; Barter PJ, 2009, 'The metabolism and anti-atherogenic properties of HDL', Journal of Lipid Research, vol. 50, http://dx.doi.org/10.1194/jlr.R800034-JLR200
Ling H; Waterworth DM; Stirnadel HA; Pollin TI; Barter PJ; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP; Cohen JC; Grundy SM; Mooser VE; Mitchell BD, 2009, 'Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: The GEMS study', Obesity, vol. 17, pp. 737 - 744, http://dx.doi.org/10.1038/oby.2008.625
Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA, 2009, 'Reconstituted High-Density Lipoprotein Increases Plasma High-Density Lipoprotein Anti-Inflammatory Properties and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes', Journal of the American College of Cardiology, vol. 53, pp. 962 - 971, http://dx.doi.org/10.1016/j.jacc.2008.12.008
Schwartz GG; Olsson AG; Ballantyne CM; Barter PJ; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Shah PK; Tardif JC; Chaitman BR; Duttlinger-Maddux R; Mathieson J, 2009, 'Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome', American Heart Journal, vol. 158, http://dx.doi.org/10.1016/j.ahj.2009.09.017
Chirovsky DR; Fedirko V; Cui Y; Sazonov V; Barter P, 2009, 'Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: A systematic review', European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, pp. 404 - 423, http://dx.doi.org/10.1097/HJR.0b013e32832c8891
Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P, 2009, 'Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib', American Heart Journal, vol. 158, http://dx.doi.org/10.1016/j.ahj.2009.07.028
Patel S; Puranik R; Nakhla S; Lundman P; Stocker R; Wang X; Lambert G; Rye KA; Barter P; Nicholls S; Celermajer D, 2009, 'Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-intlammatory capacity of high density lipoproteins', Atherosclerosis, vol. 204, pp. 424 - 428, http://dx.doi.org/10.1016/j.atherosclerosis.2008.07.047
Rye KA; Barter PJ, 2008, 'Antiinflammatory actions of HDL. A new insight', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 1890 - 1891, http://dx.doi.org/10.1161/ATVBAHA.108.173575
Barter P; Ginsberg HN, 2008, 'Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia', American Journal of Cardiology, vol. 102, pp. 1040 - 1045, http://dx.doi.org/10.1016/j.amjcard.2008.05.056
Kastelein JJP; Van Der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA; Szarek M; Larosa JC; Pedersen TR; Grundy SM, 2008, 'Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment', Circulation, vol. 117, pp. 3002 - 3009, http://dx.doi.org/10.1161/CIRCULATIONAHA.107.713438
Nobécourt E; Zeng J; Davies MJ; Brown BE; Yadav S; Barter PJ; Rye KA, 2008, 'Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I', Diabetologia, vol. 51, pp. 1008 - 1017, http://dx.doi.org/10.1007/s00125-008-0986-z
Lambert G; Ancellin N; Charlton F; Comas D; Pilot J; Keech A; Patel S; Sullivan DR; Cohn JS; Rye KA; Barter PJ, 2008, 'Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment', Clinical Chemistry, vol. 54, pp. 1038 - 1045, http://dx.doi.org/10.1373/clinchem.2007.099747
Shah SJ; Waters DD; Barter P; Kastelein JJP; Shepherd J; Wenger NK; DeMicco DA; Breazna A; LaRosa JC, 2008, 'Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery', Journal of the American College of Cardiology, vol. 51, pp. 1938 - 1943, http://dx.doi.org/10.1016/j.jacc.2007.12.054
Barter P; Shear CL; Revkin JH, 2008, 'The authors reply', New England Journal of Medicine, vol. 358, pp. 1863 - 1864
Stirnadel H; Lin X; Ling H; Song K; Barter P; Kesäniemi YA; Mahley R; McPherson R; Waeber G; Bersot T; Cohen J; Grundy S; Mitchell B; Mooser V; Waterworth D, 2008, 'Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: The GEMS Study', Atherosclerosis, vol. 197, pp. 868 - 876, http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.038
Sandhu MS; Waterworth DM; Debenham SL; Wheeler E; Papadakis K; Zhao JH; Song K; Yuan X; Johnson T; Ashford S; Inouye M; Luben R; Sims M; Hadley D; McArdle W; Barter P; Kesäniemi YA; Mahley RW; McPherson R; Grundy SM; Bingham SA; Khaw KT; Loos RJ; Waeber G; Barroso I; Strachan DP; Deloukas P; Vollenweider P; Wareham NJ; Mooser V, 2008, 'LDL-cholesterol concentrations: a genome-wide association study', The Lancet, vol. 371, pp. 483 - 491, http://dx.doi.org/10.1016/S0140-6736(08)60208-1
Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G, 2008, 'Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa', Atherosclerosis, vol. 196, pp. 659 - 666, http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.022
Barter PJ; Rye KA, 2008, 'Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 39 - 46, http://dx.doi.org/10.1161/ATVBAHA.107.148817
Puranik R; Bao S; Nobecourt E; Nicholls SJ; Dusting GJ; Barter PJ; Celermajer DS; Rye KA, 2008, 'Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo', Atherosclerosis, vol. 196, pp. 240 - 247, http://dx.doi.org/10.1016/j.atherosclerosis.2007.05.008
Settasatian N; Barter PJ; Rye KA, 2008, 'Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein', Journal of Lipid Research, vol. 49, pp. 115 - 126, http://dx.doi.org/10.1194/jlr.M700220-JLR200
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJP; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B, 2007, 'Effects of torcetrapib in patients at high risk for coronary events', New England Journal of Medicine, vol. 357, pp. 2109 - 2122, http://dx.doi.org/10.1056/NEJMoa0706628
Barter PJ; Puranik R; Rye KA, 2007, 'New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease', Current Cardiology Reports, vol. 9, pp. 493 - 498, http://dx.doi.org/10.1007/BF02938394
Balkau B; Deanfield JE; Després JP; Bassand JP; Fox KAA; Smith SC; Barter P; Tan CE; Van Gaal L; Wittchen HU; Massien C; Haffner SM, 2007, 'International day for the evaluation of abdominal obesity (IDEA): A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries', Circulation, vol. 116, pp. 1942 - 1951, http://dx.doi.org/10.1161/CIRCULATIONAHA.106.676379
Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJP; Bittner V; Fruchart JC, 2007, 'HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events', New England Journal of Medicine, vol. 357, pp. 1301 - 1310, http://dx.doi.org/10.1056/NEJMoa064278
Skropeta D; Settasatian C; McMahon MR; Shearston K; Caiazza D; McGrath KC; Jin W; Rader DJ; Barter PJ; Rye KA, 2007, 'N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins', Journal of Lipid Research, vol. 48, pp. 2047 - 2057, http://dx.doi.org/10.1194/jlr.M700248-JLR200
Nunn AVW; Bell J; Barter P, 2007, 'The integration of lipid-sensing and anti-inflammatory effects: How the PPARs play a role in metabolic balance', Nuclear Receptor, vol. 5, http://dx.doi.org/10.1186/1478-1336-5-1
Barter PJ; Shear CL, 2007, 'Aggressive management of obesity in children and young adults: The known challenges and potential opportunities', Clinical Pharmacology and Therapeutics, vol. 81, pp. 627 - 630, http://dx.doi.org/10.1038/sj.clpt.6100162
Kastelein JJP; Van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML, 2007, 'Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia', New England Journal of Medicine, vol. 356, pp. 1620 - 1630, http://dx.doi.org/10.1056/NEJMoa071359
Nobecourt E; Davies MJ; Brown BE; Curtiss LK; Bonnet DJ; Charlton F; Januszewski AS; Jenkins AJ; Barter PJ; Rye KA, 2007, 'The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase', Diabetologia, vol. 50, pp. 643 - 653, http://dx.doi.org/10.1007/s00125-006-0574-z
Barter P; McPherson YR; Song K; Kesäniemi YA; Mahley R; Waeber G; Bersot T; Mooser V; Waterworth D; Grundy SM, 2007, 'Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia', Journal of Clinical Endocrinology and Metabolism, vol. 92, pp. 2041 - 2045, http://dx.doi.org/10.1210/jc.2006-2219
Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJP; Grundy SM, 2006, 'Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study', Journal of the American College of Cardiology, vol. 48, pp. 1793 - 1799, http://dx.doi.org/10.1016/j.jacc.2006.07.041
Keech A; Simes J; Barter P; Best J; Scott R; Taskinen MR, 2006, 'Correction to the FIELD study report', Lancet, vol. 368, pp. 1415, http://dx.doi.org/10.1016/S0140-6736(06)69594-9
Barter P, 2006, 'Options for therapeutic intervention: How effective are the different agents?', European Heart Journal, Supplement, vol. 8, http://dx.doi.org/10.1093/eurheartj/sul041
Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J; Waters DD, 2006, 'Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study', Lancet, vol. 368, pp. 919 - 928, http://dx.doi.org/10.1016/S0140-6736(06)69292-1
Gotto AM; Barter PJ; Rye KA, 2006, 'Over-the-counter statins are worth considering in primary prevention of cardiovascular disease', Circulation, vol. 114, pp. 1310 - 1314, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.552257
Barter PJ; Rye KA, 2006, 'Homocysteine and cardiovascular disease: Is HDL the link?', Circulation Research, vol. 99, pp. 565 - 566, http://dx.doi.org/10.1161/01.RES.0000243583.39694.1f
Barter PJ; Rye KA; Gotto AM, 2006, 'The argument against the appropriateness of over-the-counter statins', Circulation, vol. 114, pp. 1315 - 1320, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.604991
Nicholls SJ; Lundman P; Harmer JA; Cutri B; Griffiths KA; Rye KA; Barter PJ; Celermajer DS, 2006, 'Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function', Journal of the American College of Cardiology, vol. 48, pp. 715 - 720, http://dx.doi.org/10.1016/j.jacc.2006.04.080
Barter PJ; Rye KA, 2006, 'Relationship between the concentration and antiatherogenic activity of high-density lipoproteins', Current Opinion in Lipidology, vol. 17, pp. 399 - 403, http://dx.doi.org/10.1097/01.mol.0000236365.40969.af
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D, 2006, 'Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating To New Targets (TNT) study', Diabetes Care, vol. 29, pp. 1220 - 1226, http://dx.doi.org/10.2337/dc05-2465
Barter P, 2006, 'Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides', Atherosclerosis Supplements, vol. 7, pp. 17 - 21, http://dx.doi.org/10.1016/j.atherosclerosissup.2006.05.003
Barter P; Rye KA, 2006, 'Are we lowering LDL cholesterol sufficiently?', Nature Clinical Practice Cardiovascular Medicine, vol. 3, pp. 290 - 291, http://dx.doi.org/10.1038/ncpcardio0555
Tso C; Martinic G; Fan WH; Rogers C; Rye KA; Barter PJ, 2006, 'High-density lipoproteins enhance progenitor-mediated endothelium repair in mice', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, pp. 1144 - 1149, http://dx.doi.org/10.1161/01.ATV.0000216600.37436.cf
Rye KA; Bright R; Psaltis M; Barter PJ, 2006, 'Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E', Journal of Lipid Research, vol. 47, pp. 1025 - 1036, http://dx.doi.org/10.1194/jlr.M500525-JLR200
Keech A; Simes R; Barter P; Best J; Scott R; Taskinen MR, 2006, 'The FIELD study - Authors' reply', Lancet, vol. 367, pp. 1142 - 1143, http://dx.doi.org/10.1016/S0140-6736(06)68501-2
Kee P; Caiazza D; Rye KA; Barrett PHR; Morehouse LA; Barter PJ, 2006, 'Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: In vivo studies in rabbits', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, pp. 884 - 890, http://dx.doi.org/10.1161/01.ATV.0000201064.89581.35
Barter PJ; Rye KA, 2006, 'Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism?', Circulation, vol. 113, pp. 1553 - 1555, http://dx.doi.org/10.1161/CIRCULATIONAHA.105.620450
Barter PJ; Kastelein JJP, 2006, 'Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease', Journal of the American College of Cardiology, vol. 47, pp. 492 - 499, http://dx.doi.org/10.1016/j.jacc.2005.09.042
Hime NJ; Drew KJ; Wee K; Barter PJ; Rye KA, 2006, 'Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit', Journal of Lipid Research, vol. 47, pp. 115 - 122, http://dx.doi.org/10.1194/jlr.M500284-JLR200
Barter P; Kastelein J, 2006, 'Translating today's science into clinical practice', Atherosclerosis Supplements, vol. 7, pp. 1 - 2, http://dx.doi.org/10.1016/j.atherosclerosissup.2006.01.001
Barter PJ; Ballantyne CM; Carmena R; Cabezas MC; Chapman MJ; Couture P; De Graaf J; Durrington PN; Faergeman O; Frohlich J; Furberg CD; Gagne C; Haffner SM; Humphries SE; Jungner I; Krauss RM; Kwiterovich P; Marcovina S; Packard CJ; Pearson TA; Reddy KS; Rosenson R; Sarrafzadegan N; Sniderman AD; Stalenhoef AF; Stein E; Talmud PJ; Tonkin AM; Walldius G; Williams KMS, 2006, 'Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel', Journal of Internal Medicine, vol. 259, pp. 247 - 258, http://dx.doi.org/10.1111/j.1365-2796.2006.01616.x
Keech A; Simes RJ; Barter P; Horng MS, 2006, 'Fenofibrate and cardiovascular events in patients with type 2 diabetes: Commentary', Journal of Clinical Outcomes Management, vol. 13
Nicholls SJ; Cutri B; Worthley SG; Kee P; Rye KA; Bao S; Barter PJ, 2005, 'Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 2416 - 2421, http://dx.doi.org/10.1161/01.ATV.0000184760.95957.d6
Yu Y; Wyszynski DF; Waterworth DM; Wilton SD; Barter PJ; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP; Ma Q; Sharma SS; Montgomery DS; Middleton LT; Sundseth SS; Mooser V; Grundy SM; Farrer LA, 2005, 'Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia', Journal of Lipid Research, vol. 46, pp. 2202 - 2213, http://dx.doi.org/10.1194/jlr.M500137-JLR200
Keech AC; Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Colman P; d'Emden M; Davis T; Drury P; Ehnholm C; Glasziou P; Hunt D; Kesaniemi YA; Laakso M; Simes RJ; Sullivan D; Whiting M; Ansquer JC; Fraitag B; Anderson N; Hankey G; Lehto S; Mann S; Romo M; Li LP; Hennekens C; MacMahon S; Pocock S; Tonkin A; Wilhelmsen L; Akauola H; Alford F; Beinart I; Bohra S; Boyages S; Connor H; Darnell D; Davoren P; Lepre F; De Looze F; Duffield A; Fassett R; Flack J; Fulcher G; Grant S; Hamwood S; Harmelin D; Jackson R; Jeffries W; Kamp M; Kritharides L; Mahar L; McCann V; McIntyre D; Moses R; Newnham H; Nicholson G; O'Brien R; Park K; Petrovsky N; Phillips P; Pinn G; Simmons D; Stanton K; Stuckey B; Sullivan DR; Suranyi M; Suthers M; Tan Y; Templer M; Topliss D; Waites JH; Watts G; Welborn T; Wyndham R; Haapamaki H; Kesaniemi A; Laakso M; Lahtela J; Levanen H; Saltevo J; Sodervik H; Taskinen M; Vanhala M; Baker J; Burton A; Dixon P; Doran J; Drury P; Dunn P; Graham N; Hamer A; Hedley J; Lloyd J; Manning P; McPherson I; Morris S, 2005, 'Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]', Cardiovascular Diabetology, vol. 4, http://dx.doi.org/10.1186/1475-2840-4-13
Barter PJ, 2005, 'Cardioprotective effects of high-density lipoproteins: The evidence strengthens', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 1305 - 1306, http://dx.doi.org/10.1161/01.ATV.0000172634.93210.5c
Barter PJ, 2005, 'Antiatherogenic properties of fibrates', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, pp. 1095 - 1096, http://dx.doi.org/10.1161/01.ATV.0000168895.21726.20
Barter PJ; Ballantyne CM, 2005, 'Discussion', International Journal of Clinical Practice, vol. 59, pp. 15 - 16, http://dx.doi.org/10.1111/j.1368-504X.2005.00539.x
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJP; Shepherd J; Wenger NK, 2005, 'Intensive lipid lowering with atorvastatin in patients with stable coronary disease', New England Journal of Medicine, vol. 352, pp. 1425 - 1435, http://dx.doi.org/10.1056/NEJMoa050461
Nicholls SJ; Dusting GJ; Cutri B; Bao S; Drummond GR; Rye KA; Barter PJ, 2005, 'Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits', Circulation, vol. 111, pp. 1543 - 1550, http://dx.doi.org/10.1161/01.CIR.0000159351.95399.50
Barter P, 2005, 'TNT - Atorvastatin 80 mg shows additional benefit', British Journal of Cardiology, vol. 12, pp. 95
Wyszynski DF; Waterworth DM; Barter PJ; Cohen J; Kesäniemi YA; Mahley RW; McPherson R; Waeber G; Bersot TP; Sharma SS; Nolan V; Middleton LT; Sundseth SS; Farrer LA; Mooser V; Grundy SM, 2005, 'Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)', American Journal of Cardiology, vol. 95, pp. 194 - 198, http://dx.doi.org/10.1016/j.amjcard.2004.08.091
Nicholls SJ; Rye KA; Barter PJ, 2005, 'High-density lipoproteins as therapeutic targets', Current Opinion in Lipidology, vol. 16, pp. 345 - 349, http://dx.doi.org/10.1097/01.mol.0000169356.58513.25
Stender S; Schuster H; Barter P; Watkins C; Kallend D, 2005, 'Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial', Diabetes, Obesity and Metabolism, vol. 7, pp. 430 - 438, http://dx.doi.org/10.1111/j.1463-1326.2004.00450.x
Barter PJ; O'Brien R; Watts GF; Zhu J; Hu D; Ho CC; Tomlinson B; Cheung BMY; Adam JMF; Tjokroprawiro A; Waspadji S; Cho HK; Han KH; Kim SR; Lin KK; Chan SP; Basit A; Pizzaro-Borromeo AB; Paz-Pacheco E; Sy RG; Lee KO; Low LP; Khue NT; Binh TV, 2005, 'Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: An Asian/Pacific consensus', British Journal of Diabetes and Vascular Disease, vol. 5, http://dx.doi.org/10.1177/1474651405005002s0101
Tonkin A; Barter P; Best J; Boyden A; Furler J; Hossack K; Sullivan D; Thompson P; Vale M; Cooper C; Robinson M; Clune E, 2005, 'National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.', Heart, lung & circulation, vol. 14, pp. 275 - 291, http://dx.doi.org/10.1016/j.hlc.2005.10.010
Barter P, 2005, 'The realities of dyslipidaemia in metabolic syndrome and diabetes', British Journal of Diabetes and Vascular Disease, vol. 5, http://dx.doi.org/10.1177/1474651405005001s0301
Barter P, 2005, 'The inflammation: Lipoprotein cycle', Atherosclerosis Supplements, vol. 6, pp. 15 - 20, http://dx.doi.org/10.1016/j.atherosclerosissup.2005.02.004
Barter P; Best J; Colman P; d'Emden M; Davis T; Drury P; Ehnholm C; Glasziou P; Hunt D; Keech A; Kesaniemi Y; Laakso M; Scott R; Simes R; Sullivan D; Taskinen MR; Whiting M; Ansquer JC; Fraitag B; Anderson N; Hankey G; Lehto S; Mann S; Romo M; Li L; Hennekens C; MacMahon S; Pocock S; Tonkin A; Wilhelmsen L; Forder P; Akauola H; Alford F; Beinart I; Bohra S; Connor H; Darnell D; Davoren P; Lepre F; De Looze F; Duffield A; Fassett R; Flack J; Fulcher G; Grant S; Hamwood S; Harmelin D; Jackson R; Jeffries W; Kamp M; Kritharides L; Mahar L; McCann V; McIntyre D; Moses R; Newnham H; Nicholson G; O'Brien R; Park K; Petrovsky N; Phillips P; Pinn G; Simmons D; Stanton K; Stuckey B; Sullivan DR; Suranyi M; Suthers M; Tan Y; Templer M; Topliss D; Waites JH; Watts G; Welborn T; Wyndham R; Haapamaki H; Kesaniemi A; Lahtela J; Levanen H; Saltevo J; Sodervik H; Vanhala M; Baker J; Burton A; Dixon P; Doran J; Dunn P; Graham N; Hamer A; Hedley J; Lloyd J; Manning P; McPherson I; Morris S; Renner C; Smith R; Wackrow M; Young S; Alard F, 2004, 'The need for a large-scale trial of fibrate therapy in diabetes: The rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]', Cardiovascular Diabetology, vol. 3, http://dx.doi.org/10.1186/1475-2840-3-9
Barter PJ; Nicholls S; Rye KA; Anantharamaiah GM; Navab M; Fogelman AM, 2004, 'Antiinflammatory properties of HDL', Circulation Research, vol. 95, pp. 764 - 772, http://dx.doi.org/10.1161/01.RES.0000146094.59640.13
Hime NJ; Drew KJ; Hahn C; Barter PJ; Rye KA, 2004, 'Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner', Biochemistry, vol. 43, pp. 12306 - 12314, http://dx.doi.org/10.1021/bi036305i
Barter P, 2004, 'Metabolic abnormalities: High-density lipoproteins', Endocrinology and Metabolism Clinics of North America, vol. 33, pp. 393 - 403, http://dx.doi.org/10.1016/j.ecl.2004.03.006
Wadham C; Albanese N; Roberts J; Wang L; Bagley CJ; Gamble JR; Rye KA; Barter PJ; Vadas MA; Xia P, 2004, 'High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity', Circulation, vol. 109, pp. 2116 - 2122, http://dx.doi.org/10.1161/01.CIR.0000127419.45975.26
Barter P, 2004, 'Global guidelines: National issues', International Congress Series, vol. 1262, pp. 184 - 187, http://dx.doi.org/10.1016/j.ics.2003.11.021
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glaszlou P; White H; Barter P; Tonkin A, 2004, 'Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: Results from the LIPID study', European Heart Journal, vol. 25, pp. 771 - 777, http://dx.doi.org/10.1016/j.ehj.2004.03.013
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A, 2004, 'Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study', American Heart Journal, vol. 147, pp. 705 - 712, http://dx.doi.org/10.1016/j.ahj.2003.10.004
Rye KA; Barter PJ, 2004, 'Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, pp. 421 - 428, http://dx.doi.org/10.1161/01.ATV.0000104029.74961.f5
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG, 2004, 'Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.', Atherosclerosis. Supplements, vol. 5, pp. 115 - 123, http://dx.doi.org/10.1016/j.atherosclerosissup.2004.08.032
Carrick S; Ghersi D; Wilcken N; Simes J, 2004, 'Platinum containing regimens for metastatic breast cancer', The Cochrane database of systematic reviews, pp. CD003374
Barter P, 2004, 'HDL: A recipe for longevity', Atherosclerosis Supplements, vol. 5, pp. 25 - 31, http://dx.doi.org/10.1016/j.atherosclerosissup.2004.03.003
Duong MN; Psaltis M; Rader DJ; Marchadier D; Barter PJ; Rye KA, 2003, 'Evidence That Hepatic Lipase and Endothelial Lipase Have Different Substrate Specificities for High-Density Lipoprotein Phospholipids', Biochemistry, vol. 42, pp. 13778 - 13785, http://dx.doi.org/10.1021/bi034990n
Rye KA; Wee K; Curtiss LK; Bonnet DJ; Barter PJ, 2003, 'Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation', Journal of Biological Chemistry, vol. 278, pp. 22530 - 22536, http://dx.doi.org/10.1074/jbc.M213250200
Barter P; Kastelein J; Nunn A; Hobbs R; Shepherd J; Ballantyne C; Brown V; Bruckert E; Carmena R; Davidson M; Davignon J; Fruchart JC; Gotto A; Genest J; Krone W; Leiter L; Olsson A; Packard C; Paoletti R; Saito Y; Tonkin A, 2003, 'High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions', Atherosclerosis, vol. 168, pp. 195 - 211, http://dx.doi.org/10.1016/S0021-9150(03)00006-6
Barter PJ; Brewer HB; Chapman MJ; Hennekens CH; Rader DJ; Tall AR, 2003, 'Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, pp. 160 - 167, http://dx.doi.org/10.1161/01.ATV.0000054658.91146.64
Barter P, 2003, 'Reconsidering the value of fibrates: Lessons from the trials', British Journal of Diabetes and Vascular Disease, vol. 3, pp. 162 - 167, http://dx.doi.org/10.1177/14746514030030030201
Packard C; Nunn A; Hobbs R; Barter P; Shepherd J; Kastelein J; Ballantyne C; Brown V; Bruckert E; Carmena R; Davidson M; Davignon J; Fruchrart JC; Gotto A; Genest J; Krone W; Leiter L; Olsson A; Paoletti R; Saito Y; Tonkin A, 2002, 'High density Lipoprotein: Guardian of the vascular system?', International Journal of Clinical Practice, vol. 56, pp. 761 - 771
Kee P; Rye KA; Taylor JL; Barrett PHR; Barter PJ, 2002, 'Metabolism of ApoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: Studies in wild-type and hepatic lipase transgenic rabbits', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, pp. 1912 - 1917, http://dx.doi.org/10.1161/01.ATV.0000038485.94020.7F
Barter P, 2002, 'Effects of inflammation on high-density lipoproteins', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, pp. 1062 - 1063, http://dx.doi.org/10.1161/01.ATV.0000024683.73431.99
Barter PJ, 2002, 'Coronary plaque regression: Role of low density lipoprotein-apheresis', Journal of the American College of Cardiology, vol. 40, pp. 228 - 230, http://dx.doi.org/10.1016/S0735-1097(02)01961-7
Barter PJ, 2002, 'Gemfibrozil', Journal of Drug Evaluation: Cardiovascular Medicine, vol. 1, pp. 13 - 39
Barter PJ; Baker PW; Rye KA, 2002, 'Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells', Current Opinion in Lipidology, vol. 13, pp. 285 - 288, http://dx.doi.org/10.1097/00041433-200206000-00008
Rye K; Duong M; Psaltis MK; Curtiss LK; Bonnet DJ; Stocker R; Barter P, 2002, 'Evidence that Phospholipids Play a Key Role in Pre-B ApoA-I Formation and High-Density Lipoprotein Remodeling', Biochemistry, vol. 41, pp. 12538 - 12545, http://dx.doi.org/10.1021/bi025998k
Barter P, 2001, 'Anti-atherogenic effects of fibrates in type 2 diabetes', Current Controlled Trials in Cardiovascular Medicine, vol. 2, pp. 218 - 220, http://dx.doi.org/10.1186/CVM-2-5-218
MacMahon S; Neal B; Tzourio C; Rodgers A; Woodward M; Cutler J; Anderson C; Chalmers J; Ohkubo T; Bouser MG; Davis S; Donnan G; Hansson L; Harrap S; Lees KR; Liu L; Mancia G; Omae T; Reid J; Sega R; Terent A; Warlow C; Anderson N; Bladin C; Chambers B; Gordon G; Sharpe N; Collins R; Sandercock P; Simes J; Sleight P; Brnabic A; Colman S; Francis L; Lee A; Gong L; Bousser MG; Yamaguchi T; William F; Deng Q; Hu DX; Wang W; Wu AL; Ma LY; Tao ZY; Biousse V; Berthet K; Ben Slamia L; Le Denmat C; Crespi S; Foglia G; Fujimoto C; Matsumura S; Marttala K; Pettersson M; Safwenberg M; Fenton J; McIlvenna Y; Currie R; Bartram H; Briad J; Clague A; Cleverly Y; Cosson M; Culpan A; Douglas D; Flett S; Gray B; Holloway T; Milne A; Prasad R; Ratnasabapathy Y; Santos A; Wills M; Agnew T; Chapman N; Lewis N; Mullane B, 2001, 'Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack', Lancet, vol. 358, pp. 1033 - 1041, http://dx.doi.org/10.1016/S0140-6736(01)06178-5
Barter PJ; Rye KA, 2001, 'Cholesteryl ester transfer protein, high density lipoprotein and arterial disease', Current Opinion in Lipidology, vol. 12, pp. 377 - 382, http://dx.doi.org/10.1097/00041433-200108000-00002
Clay MA; Pyle DH; Rye KA; Vadas MA; Gamble JR; Barter PJ, 2001, 'Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins', Atherosclerosis, vol. 157, pp. 23 - 29, http://dx.doi.org/10.1016/S0021-9150(00)00659-6
Tallis GA; Hamilton-Craig I; Watts GF; Barter PJ; Dimmitt SB, 2001, 'Normocholesterolaemic dyslipidaemia: Is there a role for fibrates? (multiple letters)', Medical Journal of Australia, vol. 174, pp. 610 - 611, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143458.x
Hime NJ; Barter PJ; Rye KA, 2001, 'Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II', Biochemistry, vol. 40, pp. 5496 - 5505, http://dx.doi.org/10.1021/bi0016671
Watts GF; Dimmitt SB; Barter PJ, 2001, 'Normocholesterolaemic dyslipidaemia: Is there a role for fibrates?', Medical Journal of Australia, vol. 174, pp. 66 - 67, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143155.x
Ashby D; Gamble J; Vadas M; Fidge N; Siggins S; Rye KA; Barter PJ, 2001, 'Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression', Atherosclerosis, vol. 154, pp. 113 - 121, http://dx.doi.org/10.1016/S0021-9150(00)00437-8
Thompson GR; Barter PJ, 2000, 'Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease', Current Opinion in Lipidology, vol. 11, pp. 567 - 570, http://dx.doi.org/10.1097/00041433-200012000-00001
Baker PW; Rye KA; Gamble JR; Vadas MA; Barter PJ, 2000, 'Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression', Journal of Lipid Research, vol. 41, pp. 1261 - 1267
Clay MA; Pyle DH; Rye KA; Barter PJ, 2000, 'Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase', Journal of Biological Chemistry, vol. 275, pp. 9019 - 9025, http://dx.doi.org/10.1074/jbc.275.12.9019
Barter PJ; O'Brien RC, 2000, 'Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice', Atherosclerosis, vol. 149, pp. 199 - 205, http://dx.doi.org/10.1016/S0021-9150(99)00402-5
Barter P, 2000, 'CETP and atherosclerosis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, pp. 2029 - 2031, http://dx.doi.org/10.1161/01.ATV.20.9.2029
Thompson GR; Barter PJ, 1999, 'Clinical lipidology at the end of the millennium', Current Opinion in Lipidology, vol. 10, pp. 521 - 526, http://dx.doi.org/10.1097/00041433-199912000-00007
Xia P; Vadas MA; Rye KA; Barter PJ; Gamble JR, 1999, 'High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against a therosclerosis by HDL', Journal of Biological Chemistry, vol. 274, pp. 33143 - 33147, http://dx.doi.org/10.1074/jbc.274.46.33143
Rye KA; Clay MA; Barter PJ, 1999, 'Remodelling of high density lipoproteins by plasma factors', Atherosclerosis, vol. 145, pp. 227 - 238, http://dx.doi.org/10.1016/S0021-9150(99)00150-1
Baker PW; Rye KA; Gamble JR; Vadas MA; Barter PJ, 1999, 'Ability of reconstituted high density lipoproteins to inhibit cytokine- induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells', Journal of Lipid Research, vol. 40, pp. 345 - 353
Clay MA; Cehic DA; Pyle DH; Rye KA; Barter PJ, 1999, 'Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II', Biochemical Journal, vol. 337, pp. 445 - 451, http://dx.doi.org/10.1042/0264-6021:3370445
Xia P; Gamble JR; Rye KA; Wang L; Hii CST; Cockerill P; Khew-Goodall Y; Bert AG; Barter PJ; Vadas MA, 1998, 'Tumor necrosis factor-α induces adhesion molecule expression through the sphingosine kinase pathway', Proceedings of the National Academy of Sciences of the United States of America, vol. 95, pp. 14196 - 14201, http://dx.doi.org/10.1073/pnas.95.24.14196
Tonkin A; Alyward P; Colquhoun D; Glasziou P; Harris P; Hunt D; Keech A; MacMahon S; Magnus P; Newel D; Nestel P; Sharpe N; Shaw J; Simes RJ; Thompson P; Thompson A; West M; White H; Simes S; Hague W; Caleo S; Hall J; Martin A; Mulray S; Barter P; Beilin L; Collins R; McNeil J; Meier P; Willimott H; Smithers D; Wallace P; Baker J; Hobbs M; Sullivan D; Anderson N; Hankey G; Watson J; Arulchelvam M; Chup S; Daly J; Hanna J; Leach A; Lee M; Loughhead J; Lundie-Jenkin H; Morrison J; Netting S; Nguyen A; Pater H; Philip R; Pinna G; Rattos D; Ryerson S; Sazhin V; Walsh R; Claque A; Mackie M; Yallop J; Boss K; Shepard M; Leach J; Gandy M; Joughin J; Seabrook J; Abraham R; Allen J; Bates F; Beinart I; Breed E; Brown D; Bunyan N; Calvert D; Campbell T; Condon-Paoloni D; Conway B; Coupland L; Crowe J; Cunio N; Cuthbert B; Cuthbert N; D'Arcy S; Davidson P; Dwyer B; England J; Friend C; Fulcher G; Grant S; Hellestrand K; Kava M; Kritharides L; McGill D; McKee H; McLean A; Neaverson M; Nelson G; O'Neill M; Onuma C; O'Reilly F, 1998, 'Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels', New England Journal of Medicine, vol. 339, pp. 1349 - 1357, http://dx.doi.org/10.1056/NEJM199811053391902
Hime NJ; Barter PJ; Rye KA, 1998, 'The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol', Journal of Biological Chemistry, vol. 273, pp. 27191 - 27198, http://dx.doi.org/10.1074/jbc.273.42.27191
Contacos C; Barter PJ; Vrga L; Sullivan DR, 1998, 'Cholesteryl ester transfer in hypercholesterolaemia: Fasting and postprandial studies with and without pravastatin', Atherosclerosis, vol. 141, pp. 87 - 98, http://dx.doi.org/10.1016/S0021-9150(98)00151-8
Rye KA; Jauhiainen M; Barter PJ; Ehnholm C, 1998, 'Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein', Journal of Lipid Research, vol. 39, pp. 613 - 622
Ashby DT; Rye KA; Clay MA; Vadas MA; Gamble JR; Barter PJ, 1998, 'Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, pp. 1450 - 1455, http://dx.doi.org/10.1161/01.ATV.18.9.1450
James MJ; Van Reyk D; Rye KA; Dean RT; Cleland LG; Barter PJ; Jessup W, 1998, 'Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized', Lipids, vol. 33, pp. 1115 - 1121, http://dx.doi.org/10.1007/s11745-998-0313-8
Barter P, 1998, 'Cholesterol and coronary risk: Key issues in 1998', Modern Medicine of Australia, vol. 41, pp. 101 - 107
Barter P, 1998, 'Atorvastatin: Answers to some important questions', Modern Medicine of Australia, vol. 41, pp. 114 - 115
Barter P; Sullivan D; Lloyd L; Fletcher P; Nestel P; Simons L; Butler J; Pitt A, 1997, 'NHF Guidelines on Managing Lipids: NHF Review of New Studies Confirms Importance of Managing Lipids', Current Therapeutics, vol. 38, pp. 35 - 39
Rye KA; Hime NJ; Barter PJ, 1997, 'Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion', Journal of Biological Chemistry, vol. 272, pp. 3953 - 3960, http://dx.doi.org/10.1074/jbc.272.7.3953
Vadas MA; Gamble JR; Rye K; Barter P, 1997, 'Regulation of leucocyte-endothelial interactions of special relevance to atherogenesis', Clinical and Experimental Pharmacology and Physiology, vol. 24, pp. a33 - a35, http://dx.doi.org/10.1111/j.1440-1681.1997.tb03052.x
Nestel P; Simons LA; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan DR, 1997, 'A comparative study of the efficacy of simvastatin and gemfiBrozil in comBined hyperlipoproteinemia: prediction of response By Baseline lipids, apo E genotype, lipoprotein(a) and insulin', Atherosclerosis, vol. 129, pp. 231 - 239, http://dx.doi.org/10.1016/S0021-9150(96)06031-5
Liang HQ; Rye KA; Barter PJ, 1996, 'Remodelling of reconstituted high density lipoproteins by lecithin:cholesterol acyltransferase', Journal of Lipid Research, vol. 37, pp. 1962 - 1979
Clay MA; Barter PJ, 1996, 'Formation of new HDL particles from lipid-free apolipoprotein A-I', Journal of Lipid Research, vol. 37, pp. 1722 - 1732
Rye KA; Hime NJ; Barter PJ, 1996, 'The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteines', Journal of Biological Chemistry, vol. 271, pp. 4243 - 4250, http://dx.doi.org/10.1074/jbc.271.8.4243
Kee P; Bais R; Sobecki SK; Branford S; Rye KA; Barter PJ, 1996, 'Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E', Annals of Clinical Biochemistry, vol. 33, pp. 119 - 126, http://dx.doi.org/10.1177/000456329603300204
Barter PJ; Rye KA, 1996, 'High density lipoproteins and coronary heart disease', Atherosclerosis, vol. 121, pp. 1 - 12, http://dx.doi.org/10.1016/0021-9150(95)05675-0
Barter PJ; Rye KA, 1996, 'Molecular mechanisms of reverse cholesterol transport', Current Opinion in Lipidology, vol. 7, pp. 82 - 87, http://dx.doi.org/10.1097/00041433-199604000-00006
Barter PJ, 1995, 'Management of low HDL cholesterol.', Australian family physician, vol. 24
Liang HQ; Rye KA; Barter PJ, 1995, 'Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1257, pp. 31 - 37, http://dx.doi.org/10.1016/0005-2760(95)00055-H
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL; Clapp-Channing N; Knight JD; Harrell FE; Simes J; Topol EJ; Lee KL, 1995, 'Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction', New England Journal of Medicine, vol. 332, pp. 1418 - 1424, http://dx.doi.org/10.1056/NEJM199505253322106
Rye KA; Hime NJ; Barter PJ, 1995, 'The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins', Journal of Biological Chemistry, vol. 270, pp. 189 - 196, http://dx.doi.org/10.1074/jbc.270.1.189
Cockerill GW; Rye KA; Gamble JR; Vadas MA; Barter PJ, 1995, 'High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, pp. 1987 - 1994, http://dx.doi.org/10.1161/01.ATV.15.11.1987
Barter P; Rye KA, 1994, 'Erratum: Cholesteryl ester transfer protein: Its role in plasma lipid transport (Clinical and Experimental Pharmacology and Physiology, Vol. 21 (663-672))', Clinical and Experimental Pharmacology and Physiology, vol. 21, pp. 933
Barbash GI; White HD; Modan M; Diaz R; Hampton JR; Heikkila J; Kristinsson A; Moulopoulos S; Paolasso EAC; Van Der Werf T; Pehrsson K; Sandoe E; Simes J; Wilcox RG; Verstraete M; Von Der Lippe G; Van Werf F, 1994, 'Outcome of Thrombolytic Therapy in Relation to Hospital Size and Invasive Cardiac Services', Archives of Internal Medicine, vol. 154, pp. 2237 - 2242, http://dx.doi.org/10.1001/archinte.1994.00420190141016
Rye KA; Barter PJ, 1994, 'The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins', Journal of Biological Chemistry, vol. 269, pp. 10298 - 10303
Liang HQ; Rye KA; Barter PJ, 1994, 'Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins', Journal of Lipid Research, vol. 35, pp. 1187 - 1199
Barter PJ; Rye KA, 1994, 'High-density lipoproteins and coronary heart disease', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 1, pp. 217 - 221, http://dx.doi.org/10.1177/174182679400100306
Barter P; Rye K, 1994, 'CHOLESTERYL ESTER TRANSFER PROTEIN: ITS ROLE IN PLASMA LIPID TRANSPORT', Clinical and Experimental Pharmacology and Physiology, vol. 21, pp. 663 - 672, http://dx.doi.org/10.1111/j.1440-1681.1994.tb02569.x
Barter P, 1994, 'Cholesterol and cardiovascular disease: basic science', Australian and New Zealand Journal of Medicine, vol. 24, pp. 83 - 88, http://dx.doi.org/10.1111/j.1445-5994.1994.tb04441.x
Barter PJ, 1994, 'Overview', European Journal of Cardiovascular Prevention & Rehabilitation, vol. 1, pp. 193 - 196, http://dx.doi.org/10.1177/174182679400100301
Barter P, 1994, 'HDL cholesterol: To treat or not to treat?', Modern Medicine of Australia, vol. 37, pp. 43 - 45+47+49+51
Rye KA; Garrety KH; Barter PJ, 1993, 'Preparation and characterization of spheroidal, reconstituted high-density lipoproteins with apolipoprotein A-I only or with apolipoprotein A-I and A-II', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1167, pp. 316 - 325, http://dx.doi.org/10.1016/0005-2760(93)90235-2
Barter PJ; Rajaram OV; Liang HQ; Rye KA, 1993, 'Relationship between the size and phospholipid content of low-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1166, pp. 135 - 137, http://dx.doi.org/10.1016/0005-2760(93)90294-J
Ebert DL; Warren RJ; Barter PJ; Mitchell A, 1993, 'Infusion of atherogenic lipoprotein particles increases hepatic lipase activity in the rabbit', Journal of Lipid Research, vol. 34, pp. 89 - 94
Barter P, 1993, 'High-density lipoproteins and reverse cholesterol transport', Current Opinion in Lipidology, vol. 4, pp. 210 - 217, http://dx.doi.org/10.1097/00041433-199306000-00006
Contacos C; Barter PJ; Sullivan DR, 1993, 'Effect of pravastatin and ω-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 13, pp. 1755 - 1762, http://dx.doi.org/10.1161/01.ATV.13.12.1755
Lagrost L; Barter PJ, 1992, 'Cholesteryl ester transfer protein promotes the association of HDL apolipoproteins A-I and A-II with LDL: potentiation by oleic acid', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1127, pp. 255 - 262, http://dx.doi.org/10.1016/0005-2760(92)90229-O
Newnham HH; Barter PJ, 1992, 'Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1125, pp. 297 - 304, http://dx.doi.org/10.1016/0005-2760(92)90059-5
Clay MA; Newnham HH; Forte TM; Barter PI, 1992, 'Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1124, pp. 52 - 58, http://dx.doi.org/10.1016/0005-2760(92)90125-F
Rye KA; Garrety KH; Barter PJ, 1992, 'Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: The role of apolipoproteins', Journal of Lipid Research, vol. 33, pp. 215 - 224
Barter PJ; Chang LBF; Rajaram OV, 1991, 'Factors regulating the distribution of cholesterol between LDL and HDL', Advances in Experimental Medicine and Biology, vol. 285, pp. 59 - 64
Warren RJ; Ebert DL; Barter PJ; Mitchell A, 1991, 'The regulation of hepatic lipase and cholesteryl ester transfer protein activity in the cholesterol fed rabbit', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1086, pp. 354 - 358, http://dx.doi.org/10.1016/0005-2760(91)90181-G
Warren RJ; Ebert DL; Mitchell A; Barter PJ, 1991, 'Rabbit hepatic lipase cDNA sequence: Low activity is associated with low messenger RNA levels', Journal of Lipid Research, vol. 32, pp. 1333 - 1339
Lagrost L; Barter PJ, 1991, 'Effects of various non-esterified fatty acids on the transfer of cholesteryl esters from HDL to LDL induced by the cholesteryl ester transfer protein', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1085, pp. 209 - 216, http://dx.doi.org/10.1016/0005-2760(91)90096-Z
Lagrost L; Barter PJ, 1991, 'Effects of various non-esterified fatty acids on the particle size redistribution of high density lipoproteins induced by the human cholesteryl ester transfer protein', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1082, pp. 204 - 210, http://dx.doi.org/10.1016/0005-2760(91)90195-N
BARTER PJ, 1991, 'High density lipoproteins and coronary heart disease', Australian and New Zealand Journal of Medicine, vol. 21, pp. 299 - 301, http://dx.doi.org/10.1111/j.1445-5994.1991.tb04693.x
Barter PJ, 1991, 'ROLE OF NON‐ESTERIFIED FATTY ACIDS IN REGULATING PLASMA CHOLESTEROL TRANSPORT', Clinical and Experimental Pharmacology and Physiology, vol. 18, pp. 77 - 79, http://dx.doi.org/10.1111/j.1440-1681.1991.tb01410.x
Meyer B; Kecorius E; Barter P; Fidge N; Tetaz T, 1991, 'Application of reversed-phase high-performance liquid chromatography to the separation of apolipoproteins A-IV, A-I and E from rat high-density lipoprotein', Journal of Chromatography A, vol. 540, pp. 386 - 391, http://dx.doi.org/10.1016/S0021-9673(01)88827-0
Clay MA; Newnham HH; Barter PJ, 1991, 'Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro', Arteriosclerosis and Thrombosis, vol. 11, pp. 415 - 422, http://dx.doi.org/10.1161/01.atv.11.2.415
Barter PJ; Chang LBF; Rajaram OV, 1990, 'Sodium oleate dissociates the heteroexchange of cholesteryl esters and triacylglycerol between HDL and triacylglycerol-rich lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1047, pp. 294 - 297, http://dx.doi.org/10.1016/0005-2760(90)90529-7
Barter PJ; Chang LBF; Newnham HH; Rye KA; Rajaram OV, 1990, 'The interaction of cholesteryl ester transfer protein and unesterified fatty acids promotes a reduction in the particle size of high-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1045, pp. 81 - 89, http://dx.doi.org/10.1016/0005-2760(90)90206-D
Clay MA; Rye KA; Barter PJ, 1990, 'Evidence in vitro that hepatic lipase reduces the concentration of apolipoprotein A-I in rabbit high-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1044, pp. 50 - 56, http://dx.doi.org/10.1016/0005-2760(90)90217-L
Newnham HH; Barter PJ, 1990, 'Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1044, pp. 57 - 64, http://dx.doi.org/10.1016/0005-2760(90)90218-M
Newnham HH; Hopkins GJ; Devlin S; Barter PJ, 1990, 'Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma', Atherosclerosis, vol. 82, pp. 167 - 176, http://dx.doi.org/10.1016/0021-9150(90)90037-J
Barter PJ; Chang LBF; Rajaram OV, 1990, 'Sodium oleate promotes a redistribution of cholesteryl esters from high to low density lipoproteins', Atherosclerosis, vol. 84, pp. 13 - 24, http://dx.doi.org/10.1016/0021-9150(90)90003-2
MACKINTOSH J; SIMES J; RAGHAVAN D; PEARSON B, 1990, 'Prostatic Cancer with Bone Metastases: Serum Alkaline Phosphatase (SAP) as a Predictor of Response and the Significance of the SAP “Flare”', British Journal of Urology, vol. 66, pp. 88 - 93, http://dx.doi.org/10.1111/j.1464-410X.1990.tb14871.x
Barter PJ, 1990, 'Enzymes involved in lipid and lipoprotein metabolism', Current Opinion in Lipidology, vol. 1, pp. 518 - 523, http://dx.doi.org/10.1097/00041433-199012000-00006
Meyer BJ; Ha YC; Barter PJ, 1989, 'Effects of experimental hypothyroidism on the distribution of lipids and lipoproteins in the plasma of rats', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1004, pp. 73 - 79, http://dx.doi.org/10.1016/0005-2760(89)90215-4
Clay MA; Hopkins GJ; Ehnholm CP; Barter PJ, 1989, 'The rabbit as an animal model of hepatic lipase deficiency', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1002, pp. 173 - 181, http://dx.doi.org/10.1016/0005-2760(89)90284-1
Hopkins GJ; Barter PJ, 1989, 'Apolipoprotein A-I inhibits transformation of high density lipoprotein subpopulations during incubation of human plasma', Atherosclerosis, vol. 75, pp. 73 - 82, http://dx.doi.org/10.1016/0021-9150(89)90209-8
Barter PJ, 1989, 'Abnormalities of cholesteryl ester transfer', Atherosclerosis VIII: proceedings of the 8th International Symposium on Atherosclerosis. ICS817, pp. 377 - 380
National Heart Foundation Of Australia Coronary Thrombolysis Group , 1988, 'CORONARY THROMBOLYSIS AND MYOCARDIAL SALVAGE BY TISSUE PLASMINOGEN ACTIVATOR GIVEN UP TO 4 HOURS AFTER ONSET OF MYOCARDIAL INFARCTION', The Lancet, vol. 331, pp. 203 - 208, http://dx.doi.org/10.1016/S0140-6736(88)91063-X
Barter PJ; Rajaram OV; Chang LBF; Rye KA; Gambert P; Lagrost L; Ehnholm C; Fidge NH, 1988, 'Isolation of a high-density-lipoprotein conversion factor from human plasma. A possible role of apoliprotein A-IV as its activator', Biochemical Journal, vol. 254, pp. 179 - 184, http://dx.doi.org/10.1042/bj2540179
Glasziou P; Hilden J; Simes J, 1988, 'Single Testing When Two Tests Are Available', Medical Decision Making, vol. 8, pp. 223, http://dx.doi.org/10.1177/0272989X8800800311
Clifton PM; Barter PJ; Mackinnon AM, 1988, 'High density lipoprotein particle size distribution in subjects with obstructive jaundice', Journal of Lipid Research, vol. 29, pp. 121 - 135
Clifton PM; MacKinnon AM; Barter PJ, 1987, 'Separation and characterization of high-density lipoprotein subpopulations by gel permeation chromatography', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 414, pp. 25 - 34, http://dx.doi.org/10.1016/0378-4347(87)80021-X
Barter PJ; Hopkins GJ; Rajaram OV, 1987, '6 Enzymes involved in plasma cholesterol transport', Bailliere's Clinical Endocrinology and Metabolism, vol. 1, pp. 623 - 638, http://dx.doi.org/10.1016/S0950-351X(87)80026-5
Barter PJ; Hopkins GJ; Ha YC, 1987, 'The role of lipid transfer proteins in plasma lipoprotein metabolism', American Heart Journal, vol. 113, pp. 538 - 542, http://dx.doi.org/10.1016/0002-8703(87)90628-4
Hopkins GJ; Barter PJ, 1986, 'Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins', Journal of Lipid Research, vol. 27, pp. 1265 - 1277
Mackinnon M; Savage J; Wishart R; Barter P, 1986, 'Metabolism of high density lipoproteins by the perfused rabbit liver', Journal of Biological Chemistry, vol. 261, pp. 2548 - 2552
Rajaram OV; Barter PJ, 1986, 'Increases in the particle size of high-density lipoproteins induced by purified lecithin: cholesterol acyltransferase: effect of low-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 877, pp. 406 - 414, http://dx.doi.org/10.1016/0005-2760(86)90206-7
Rye KA; Barter PJ, 1986, 'Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 875, pp. 429 - 438, http://dx.doi.org/10.1016/0005-2760(86)90062-7
Klein S; Simes J; Blackburn GL, 1986, 'Total parenteral nutrition and cancer clinical trials', Cancer, vol. 58, pp. 1378 - 1386, http://dx.doi.org/10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S
Chang L; Clifton P; Barter P; Mackinnon, M.D. M, 1986, 'High density lipoprotein subpopulations in chronic liver disease', Hepatology, vol. 6, pp. 46 - 49, http://dx.doi.org/10.1002/hep.1840060109
Chea Ha Y; Barter PJ, 1986, 'Effects of sucrose feeding and injection of lipid transfer protein on rat plasma lipoproteins', Comparative Biochemistry and Physiology -- Part B: Biochemistry and, vol. 83, pp. 463 - 466, http://dx.doi.org/10.1016/0305-0491(86)90396-2
Clifton PM; Mackinnon AM; Barter PJ, 1985, 'Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction', Journal of Lipid Research, vol. 26, pp. 1389 - 1398
Rajaram OV; Barter PJ, 1985, 'Reactivity of human lipoproteins with purified lecithin: cholesterol acyltransferase during incubations in vitro', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 835, pp. 41 - 49, http://dx.doi.org/10.1016/0005-2760(85)90028-1
Ha YC; Chang LBF; Barter PJ, 1985, 'Effects of injecting exogenous lipid transfer protein into rats', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 833, pp. 203 - 210, http://dx.doi.org/10.1016/0005-2760(85)90191-2
Hopkins GJ; Chang LBF; Barter PJ, 1985, 'Role of lipid transfers in the formation of a subpopulation of small high density lipoproteins', Journal of Lipid Research, vol. 26, pp. 218 - 229
Barter PJ; Hopkins GJ; Gorjatschko L, 1985, 'Lipoprotein substrates for plasma cholesterol esterification. Influence of particle size and composition of the high density lipoprotein subfraction 3', Atherosclerosis, vol. 58, pp. 97 - 107, http://dx.doi.org/10.1016/0021-9150(85)90058-9
Ha YC; Barter PJ, 1985, 'Rapid separation of plasma lipoproteins by gel permeation chromatography on agarose gel Superose 6B', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 341, pp. 154 - 159, http://dx.doi.org/10.1016/S0378-4347(00)84020-7
Chang LBF; Hopkins GJ; Barter PJ, 1985, 'Particle size distribution of high density lipoproteins as a function of plasma triglyceride concentration in human subjects', Atherosclerosis, vol. 56, pp. 61 - 70, http://dx.doi.org/10.1016/0021-9150(85)90084-X
Malcolm MacKinnon A; Savage J; Gibson RA; Barter PJ, 1985, 'Secretion of cholesteryl ester-enriched very low density lipoproteins by the liver of cholesterol-fed rabbits', Atherosclerosis, vol. 54, pp. 145 - 155, http://dx.doi.org/10.1016/0021-9150(85)90174-1
Moon EA; Mackinnon AM; Barter PJ, 1984, 'Appearance of serum amyloid protein in high-density lipoproteins of rabbits subjected to relatively mild stimuli', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 796, pp. 354 - 358, http://dx.doi.org/10.1016/0005-2760(84)90137-1
Rye KA; Barter PJ, 1984, 'Evidence of the existence of a high-density lipoprotein transformation factor in pig and rabbit plasma', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 795, pp. 230 - 237, http://dx.doi.org/10.1016/0005-2760(84)90070-5
Greenspan EM; Peterson AP; Roth GJ; Gajwani BW; Gelber R; Simes J; Zelen M; Lessner HE; Mayer RJ; Ellenberg SS; Stablein DM, 1984, 'Adjuvant Therapy for Colon Cancer', New England Journal of Medicine, vol. 311, pp. 410 - 411, http://dx.doi.org/10.1056/NEJM198408093110618
Hopkins GJ; Barter PJ, 1984, 'Capacity of lipoproteins to act as substrates for lecithin:Cholesterol acyltransferase. Enhancement by pre-incubation with an artificial triacylglycerol emulsion', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 794, pp. 31 - 40, http://dx.doi.org/10.1016/0005-2760(84)90294-7
Abbey M; Savage JK; Mackinnon AM; Barter PJ; Calvert GD, 1984, 'Detection of lipid transfer protein activity in rabbit liver perfusate', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 793, pp. 481 - 484, http://dx.doi.org/10.1016/0005-2760(84)90266-2
Abbey M; Calvert GD; Barter PJ, 1984, 'Changes in lipid and apolipoprotein composition of pig lipoproteins facilitated by rabbit lipid transfer protein', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 793, pp. 471 - 480, http://dx.doi.org/10.1016/0005-2760(84)90265-0
Barter PJ; Hopkins GJ; Gorjatschko L; Jones ME, 1984, 'Competitive inhibition of plasma cholesterol esterification by human high-density lipoprotein-subfraction 2', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 793, pp. 260 - 268, http://dx.doi.org/10.1016/0005-2760(84)90328-X
Barter PJ; Hopkins GJ; Gorjatschko L, 1984, 'Comparison of human plasma low- and high-density lipoproteins as substrates for lecithin: Cholesterol acyltransferase', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 792, pp. 1 - 5, http://dx.doi.org/10.1016/0005-2760(84)90274-1
Ying Chea Ha ; Chang LBF; Barter PJ, 1984, 'Incubation of human lipid transfer protein with plasma from normal-fed and cholesterol-fed rats: Effect on the distribution of constituents between lipoprotein fractions', Comparative Biochemistry and Physiology -- Part B: Biochemistry and, vol. 78, pp. 675 - 682, http://dx.doi.org/10.1016/0305-0491(84)90117-2
Barter PJ, 1983, 'Evidence that lecithin: Cholesterol acyltransferase acts on both high-density and low-density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 751, pp. 261 - 270, http://dx.doi.org/10.1016/0005-2760(83)90283-7
Barter PJ; Hopkins GJ, 1983, 'Relative rates of incorporation of esterified cholesterol into human very low density lipoproteins and low density lipoproteins in vitro studies of two separate pathways', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 751, pp. 33 - 40, http://dx.doi.org/10.1016/0005-2760(83)90254-0
Ha YC; Gorjatschko L; Barter PJ, 1983, 'Changes in the density distribution of pig high density lipoproteins during incubation in vitro. Influence of esterified cholesterol transfer activity', Atherosclerosis, vol. 48, pp. 253 - 263, http://dx.doi.org/10.1016/0021-9150(83)90043-6
Hopkins GJ; Barter PJ, 1983, 'Role of esterified cholesterol transfers in the regulation of plasma cholesterol esterification', Atherosclerosis, vol. 49, pp. 177 - 185, http://dx.doi.org/10.1016/0021-9150(83)90195-8
Barter PJ; Hopkins GJ; Calvert GD, 1982, 'Pathways for the incorporation of esterified cholesterol into very low density and low density lipoproteins in plasma incubated in vitro', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 713, pp. 136 - 148, http://dx.doi.org/10.1016/0005-2760(82)90176-X
Hopkins GJ; Barter PJ, 1982, 'An effect of very low density lipoproteins on the rate of cholesterol esterification in human plasma', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 712, pp. 152 - 160, http://dx.doi.org/10.1016/0005-2760(82)90097-2
Barter PJ; Gorjatschko L; Hopkins GJ, 1982, 'Comparison of different methods of isotopically labelling the esterified cholesterol in human high density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 710, pp. 349 - 358, http://dx.doi.org/10.1016/0005-2760(82)90118-7
Davis MW; Vaterlaws AL; Simes J; Torzillo P, 1982, 'Retinopathy in malaria.', Papua and New Guinea Medical Journal, vol. 25, pp. 19 - 22
Hopkins GJ; Barter PJ, 1982, 'Dissociation of the in vitro transfers of esterified cholesterol and triglyceride between human lipoproteins', Metabolism, vol. 31, pp. 78 - 81, http://dx.doi.org/10.1016/0026-0495(82)90030-0
Barter PJ; Hopkins GJ; Calvert GD, 1982, 'Transfers and exchanges of esterified cholesterol between plasma lipoproteins', Biochemical Journal, vol. 208, pp. 1 - 7, http://dx.doi.org/10.1042/bj2080001
Haa YC; Barter PJ, 1982, 'Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species', Comparative Biochemistry and Physiology -- Part B: Biochemistry and, vol. 71, pp. 265 - 269, http://dx.doi.org/10.1016/0305-0491(82)90252-8
Barter PJ; Hopkins GJ; Gorjatschko L; Jones ME, 1982, 'A unified model of esterified cholesterol exchanges between human plasma lipoproteins', Atherosclerosis, vol. 44, pp. 27 - 40, http://dx.doi.org/10.1016/0021-9150(82)90050-8
Barter PJ; Ha YC; Calvert GD, 1981, 'Studies of esterified cholesterol in sub-fractions of plasma high density lipoproteins', Atherosclerosis, vol. 38, pp. 165 - 175, http://dx.doi.org/10.1016/0021-9150(81)90113-1
Williams DR; Barter PJ; Mackinnon AM, 1981, 'Serum lecithin: Cholesterol acyltransferase activity in the bile duct-ligated rat', Digestion, vol. 21, pp. 273 - 278, http://dx.doi.org/10.1159/000198574
Ha YC; Calvert GD; McIntosh GH; Barter PJ, 1981, 'A physiologic role for the esterified cholesterol transfer protein: In vivo studies in rabbits and pigs', Metabolism, vol. 30, pp. 380 - 383, http://dx.doi.org/10.1016/0026-0495(81)90119-0
Rajaram OV; Barter PJ, 1980, 'Influence of lipoprotein concentration on the exchanges of triacylglycerol between rabbit plasma low density and high density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 620, pp. 483 - 488, http://dx.doi.org/10.1016/0005-2760(80)90140-X
Rajaram OV; White GH; Barter PJ, 1980, 'Partial purification and characterization of a triacylglycerol-transfer protein from rabbit serum', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 617, pp. 383 - 392, http://dx.doi.org/10.1016/0005-2760(80)90004-1
Barter PJ; Jones ME, 1980, 'Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins', Journal of Lipid Research, vol. 21, pp. 238 - 249
Hopkins GJ; Barter PJ, 1980, 'Transfers of esterified cholesterol and triglyceride between high density and very low density lipoproteins: In vitro studies of rabbits and humans', Metabolism, vol. 29, pp. 546 - 550, http://dx.doi.org/10.1016/0026-0495(80)90080-3
Barter PJ; Gorjatschko L; Calvert GD, 1980, 'Net mass transfer of esterified cholesterol from human low density lipoproteins to very low density lipoproteins incubated in vitro', Biochimica et Biophysica Acta - Lipids and Lipid Metabolism, vol. 619, pp. 436 - 439, http://dx.doi.org/10.1016/0005-2760(80)90095-8
Rajaram OV; Clark MG; Barter PJ, 1980, 'Differences in the metabolism of very-low-density lipoproteins by isolated beating-heart cells and the isolated perfused rat heart. Evidence for collagenase-released extracellular lipoprotein lipase', Biochemical Journal, vol. 186, pp. 431 - 438, http://dx.doi.org/10.1042/bj1860431
Wood PR; Simes RJ; Nelson DS, 1979, 'Activity of mouse macrophages purified by adherence to, and removal from, a plastic surface', Journal of Immunological Methods, vol. 28, pp. 117 - 124, http://dx.doi.org/10.1016/0022-1759(79)90333-8
Barter PJ; Lally JI, 1979, 'The metabolism of esterified cholesterol in rabbit plasma low density lipoproteins', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 572, pp. 510 - 518, http://dx.doi.org/10.1016/0005-2760(79)90158-9
Barter PJ; Lally JI, 1979, 'In vitro exchanges of esterified cholesterol between serum lipoprotein fractions: Studies of humans and rabbits', Metabolism, vol. 28, pp. 230 - 236, http://dx.doi.org/10.1016/0026-0495(79)90068-4
Ha YC; Calvert GD; Barter PJ, 1979, 'In vivo metabolism of esterified cholesterol and apoproteins in rabbit plasma low density lipoproteins', Atherosclerosis, vol. 34, pp. 451 - 455, http://dx.doi.org/10.1016/0021-9150(79)90069-8
Barter PJ; Lally JI; Wattchow D, 1979, 'Metabolism of triglyceride in rabbit plasma low and high density lipoproteins: Studies in vivo and in vitro', Metabolism, vol. 28, pp. 614 - 618, http://dx.doi.org/10.1016/0026-0495(79)90012-X
Barter PJ; Gooden JM; Rajaram OV, 1979, 'Species differences in the activity of a serum triglyceride transferring factor', Atherosclerosis, vol. 33, pp. 165 - 169, http://dx.doi.org/10.1016/0021-9150(79)90113-8
Barter PJ; Jones ME, 1979, 'Rate of exchange of esterified cholesterol between human plasma low and high density lipoproteins', Atherosclerosis, vol. 34, pp. 67 - 74, http://dx.doi.org/10.1016/0021-9150(79)90107-2
Lally JI; Barter PJ, 1979, 'The in vivo metabolism of esterified cholesterol in the plasma high-density lipoproteins of rabbits', The Journal of Laboratory and Clinical Medicine, vol. 93, pp. 570 - 582
Barter PJ; Lally JI, 1978, 'The activity of an esterified cholesterol transferring factor in human and rat serum', Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 531, pp. 233 - 236, http://dx.doi.org/10.1016/0005-2760(78)90147-9
Barter PJ; I.Lally J, 1978, 'Metabolism of esterified cholesterol in the plasma very low density lipoproteins of the rabbit. Studies in vivo and in vitro', Atherosclerosis, vol. 31, pp. 355 - 364, http://dx.doi.org/10.1016/0021-9150(78)90070-9
Barter P; Faergeman O; Havel RJ, 1977, 'Metabolism of cholesteryl esters of very low density lipoproteins in the guinea pig', Metabolism, vol. 26, pp. 615 - 622, http://dx.doi.org/10.1016/0026-0495(77)90083-X
Barter PJ; Connor WE, 1976, 'The transport of esterified cholesterol in plasma high density lipoproteins of human subjects: a mathematical model', The Journal of Laboratory and Clinical Medicine, vol. 88, pp. 627 - 639
Barter PJ; Connor WE, 1975, 'The transport of triglyceride in the high-density lipoproteins of human plasma', The Journal of Laboratory and Clinical Medicine, vol. 85, pp. 260 - 272
Barter PJ, 1974, 'Production of plasma esterified cholesterol in lean, normotriglyceridemic humans.', Journal of Lipid Research, vol. 15, pp. 234 - 242
Barter PJ; Connor WE; Spector AA; Armstrong M; Connor SL; Newman MA, 1974, 'Lowering of serum cholesterol and triglyceride by para aminosalicylic acid in hyperlipoproteinemia. Studies in patients with types II A and II B', Annals of Internal Medicine, vol. 81, pp. 619 - 624, http://dx.doi.org/10.7326/0003-4819-81-5-619
Barter PJ, 1974, 'Origin of esterified cholesterol transported in the very low density lipoproteins of human plasma', Journal of Lipid Research, vol. 15, pp. 11 - 19
Barter PJ; Nestel PJ, 1973, 'Precursors of plasma triglyceride fatty acids in obesity', Metabolism, vol. 22, pp. 779 - 785, http://dx.doi.org/10.1016/0026-0495(73)90048-6
Nestel PJ; Barter PJ, 1973, 'Triglyceride clearance during diets rich in carbohydrate or fats.', The American journal of clinical nutrition, vol. 26, pp. 241 - 245, http://dx.doi.org/10.1093/ajcn/26.3.241
Barter PJ; Nestel PJ, 1972, 'Plasma free fatty acid transport during prolonged glucose consumption and its relationship to plasma triglyceride fatty acids in man', Journal of Lipid Research, vol. 13, pp. 483 - 490
Barter PJ; Nestel PJ; Carroll KF, 1972, 'Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver', Metabolism, vol. 21, pp. 117 - 124, http://dx.doi.org/10.1016/0026-0495(72)90063-7
Barter PJ; Nestel PJ, 1972, 'Precursor-product relationship between pools of very low density lipoprotein triglyceride.', The Journal of clinical investigation, vol. 51, pp. 174 - 180, http://dx.doi.org/10.1172/JCI106789
Barter PJ; Carroll KF; Nestel PJ, 1971, 'Diurnal fluctuations in triglyceride, free fatty acids, and insulin during sucrose consumption and insulin infusion in man.', The Journal of clinical investigation, vol. 50, pp. 583 - 591, http://dx.doi.org/10.1172/JCI106528
Nestel PJ; Barter P, 1971, 'Metabolism of palmitic and linoleic acids in man: differences in turnover and conversion to glycerides.', Clinical science, vol. 40, pp. 345 - 350, http://dx.doi.org/10.1042/cs0400345
Barter PJ; Nestel PJ, 1970, 'The distribution of triglyceride in subclasses of very low density plasma lipoproteins', The Journal of Laboratory and Clinical Medicine, vol. 76, pp. 925 - 932
Conference Papers
Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW, 2015, 'Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a VOYAGER meta-analysis', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, London, ENGLAND, pp. 1151 - 1151, presented at Congress of the European-Society-of-Cardiology (ESC), London, ENGLAND, 29 August 2015 - 02 September 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361205107481&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'Reductions in Low-Density Lipoprotein Cholesterol and Triglyceride with Statins in Patients with Hypertriglyceridaemia: Results from VOYAGER', in CARDIOLOGY, KARGER, pp. 28 - 29, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000355945200046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'Distribution of LDL-C Reduction with Atorvastatin, Rosuvastatin and Simvastatin: A VOYAGER Meta-Analysis', in CARDIOLOGY, KARGER, pp. 26 - 27, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000355945200044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'Equipotent Effects of Rosuvastatin, Atorvastatin and Simvastatin on LDL-C Reduction: Results from the Voyager Meta-Analysis', in CARDIOLOGY, KARGER, pp. 20 - 20, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000355945200035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'PREDICTING THE REDUCTION IN RISK OF CARDIOVASCULAR EVENTS WITH HIGH-INTENSITY STATIN TREATMENT: A VOYAGER ANALYSIS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Glasgow, SCOTLAND, pp. E202 - E203, presented at 83rd Congress of the European-Atherosclerosis-Society (EAS), Glasgow, SCOTLAND, 22 March 2015 - 25 March 2015, http://dx.doi.org/10.1016/j.atherosclerosis.2015.04.974
Palmer M; Nicholls SJ; Lundman P; Barter PJ; Karlson BW, 2015, 'ESTIMATING THE REDUCTION IN 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH STATIN THERAPY: A VOYAGER META-ANALYSIS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Glasgow, SCOTLAND, pp. E21 - E22, presented at 83rd Congress of the European-Atherosclerosis-Society (EAS), Glasgow, SCOTLAND, 22 March 2015 - 25 March 2015, http://dx.doi.org/10.1016/j.atherosclerosis.2015.04.088
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in the four statin benefit groups identified by the ACC/AHA 2013 guidelines? A VOYAGER meta-analysis', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, Barcelona, SPAIN, pp. 679 - 679, presented at Annual Meeting of the European-Society-of-Cardiology (ESC), Barcelona, SPAIN, 30 August 2014 - 03 September 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343001304110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'Impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridaemia: a VOYAGER meta-analysis', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, Barcelona, SPAIN, pp. 217 - 217, presented at Annual Meeting of the European-Society-of-Cardiology (ESC), Barcelona, SPAIN, 30 August 2014 - 03 September 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343001301161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'ATTAINMENT OF THE ANTICIPATED >=50% REDUCTION IN LDL-C IN THE FOUR ACC/AHA GUIDELINES STATIN BENEFIT GROUPS: A VOYAGER META-ANALYSIS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Spanish Soc Atherosclerosis, Madrid, SPAIN, pp. E11 - E12, presented at 82nd Congress of the European-Atherosclerosis-Society (EAS), Spanish Soc Atherosclerosis, Madrid, SPAIN, 31 May 2014 - 03 June 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.003
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'DOSES OF ROSUVASTATIN, ATORVASTATIN AND SIMVASTATIN INDUCING AN EQUIPOTENT EFFECT ON LDL-C: RESULTS FROM THE VOYAGER META-ANALYSIS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Spanish Soc Atherosclerosis, Madrid, SPAIN, pp. E35 - E35, presented at 82nd Congress of the European-Atherosclerosis-Society (EAS), Spanish Soc Atherosclerosis, Madrid, SPAIN, 31 May 2014 - 03 June 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.071
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2014, 'VARIABILITY OF LDL-C RESPONSE WITH DIFFERENT DOSES OF SIMVASTATIN, ATORVASTATIN AND ROSUVASTATIN: RESULTS FROM VOYAGER', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Spanish Soc Atherosclerosis, Madrid, SPAIN, pp. E295 - E295, presented at 82nd Congress of the European-Atherosclerosis-Society (EAS), Spanish Soc Atherosclerosis, Madrid, SPAIN, 31 May 2014 - 03 June 2014, http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.889
Fryirs MA; Barter PJ; Appavoo M; Tuch B; Tabet F; Heater AK; Rye KA, 2009, 'High Density Lipoproteins Increase the Insulin Secretory Capacity of Pancreatic beta-Cells', in DIABETES, AMER DIABETES ASSOC, New Orleans, LA, pp. A426 - A426, presented at 69th Annual Meeting of the American-Diabetes-Association, New Orleans, LA, 05 June 2009 - 09 June 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000266352602394&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Barter PJ; Rye KA, 2006, 'The rationale for using apoA-I as a clinical marker of cardiovascular risk', in Journal of Internal Medicine, pp. 447 - 454, http://dx.doi.org/10.1111/j.1365-2796.2006.01647.x
Barter P, 2005, 'The role of HDL-cholesterol in preventing atherosclerotic disease', in European Heart Journal, Supplement, http://dx.doi.org/10.1093/eurheartj/sui036
Barter P; Hanefeld M, 2005, 'Dyslipidaemia and the metabolic syndrome: Critical issues in improving CVD risk reduction', in British Journal of Diabetes and Vascular Disease, http://dx.doi.org/10.1177/1474651405005001s0101
Barter P, 2004, 'Is high-density lipoprotein the protector of the cardiovascular system?', in European Heart Journal, Supplement, http://dx.doi.org/10.1016/j.ehjsup.2004.01.005
Barter P, 2003, 'Lipids, inflammation and CVD - Understanding the basics to break the atherosclerosis cycle: Introduction', in International Journal of Clinical Practice, Supplement, pp. 2 - 4
Ballantyne CM; Stein EA; Paoletti R; Southworth H; Blasetto JW; Barter P; Rader DJ, 2003, 'Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome', in American Journal of Cardiology, pp. 25 - 27, http://dx.doi.org/10.1016/S0002-9149(03)00006-7
Rader DJ; Davidson MH; Caplan RJ; Pears JS; Stein EA; Shepherd J; Barter P; Hobbs R, 2003, 'Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin', in American Journal of Cardiology, pp. 20 - 23, http://dx.doi.org/10.1016/S0002-9149(03)00005-5
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG; Davidson MH, 2003, 'Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals', in American Journal of Cardiology, pp. 11 - 17, http://dx.doi.org/10.1016/S0002-9149(03)00004-3
Barter PJ, 2003, 'In a modern world, atherosclerosis is an almost evolutionary certuinty: Introduction', in International Journal of Clinical Practice, Supplement, pp. 2
Barter PJ, 2002, 'Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors', in Atherosclerosis Supplements, pp. 39 - 47, http://dx.doi.org/10.1016/S1567-5688(02)00041-7
Barter P, 2002, 'Treatment of dyslipidaemia in high-risk patients: Too little, too late', in International Journal of Clinical Practice, Supplement, pp. 15 - 19
Shepherd J; Barter P, 2002, 'Lipid-lowering - Translating evidence into benefits', in Atherosclerosis Supplements, pp. 1 - 3, http://dx.doi.org/10.1016/S1567-5688(01)00015-0
Barter PJ; Sacks FM, 2001, 'Threshold level or not for low-density lipoprotein cholesterol', in American Journal of Managed Care
Barter P, 2000, 'Cholesterol management: How to implement best practice', in European Heart Journal, Supplement
Lacko AG; Barter P; Ehnholm C; Van Tol A, 2000, 'International symposium on basic aspects of HDL metabolism and disease prevention', in Journal of Lipid Research, pp. 1695 - 1699
Barter PJ, 2000, 'Treating to target with statins', in Atherosclerosis Supplements, pp. 21 - 25, http://dx.doi.org/10.1016/S0021-9150(00)00564-5
Barter P, 1999, 'The National Heart Foundation's research program', in Asia Pacific Heart Journal, pp. 178 - 180, http://dx.doi.org/10.1016/S1328-0163(99)90058-1
Barter PJ, 1997, 'Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins', in Clinical and Experimental Pharmacology and Physiology, pp. 286 - 287, http://dx.doi.org/10.1111/j.1440-1681.1997.tb01821.x
Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E, 1993, 'Ifosfamide combination regimens for soft-tissue sarcoma', in Cancer Chemotherapy and Pharmacology
Beilin L; Heller R; Butler J; Simes J; Calvert D; Birkett D; Sullivan D; Mudge P; Kniha E; Thompson P; Marley J, 1992, 'The management of hyperlipidaemia: A consensus statement', in Medical Journal of Australia
Barter PJ; Chang LBF; Newnham HH; Rye KA; Rajaram OV, 1990, 'Roles of lecithin: Cholesterol acyltransferase, lipid transfer proteins and nonesterified fatty acids in plasma cholesterol transport', in Journal of Drug Development, Supplement, pp. 85 - 89
Barter PJ, 1977, 'POPULATION SCREENING FOR PLASMA LIPIDS', in Australian and New Zealand Journal of Medicine, pp. 675 - 675, http://dx.doi.org/10.1111/j.1445-5994.1977.tb02355.x
Conference Abstracts
Cochran BJ; Pinheiro D; Prendecki M; Jones B; Cegla J; Lee V; Barter PJ; Murphy AJ; Rye K-A; Woollard KJ, 2018, 'PRO-ATHEROSCLEROTIC LOW-DENSITY NEUTROPHILS ARE PRESENT IN HYPERCHOLESTEROLEMIA', in ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER IRELAND LTD, Toronto, CANADA, Vol. 32, pp. 39 - 40, presented at International Symposium on Atherosclerosis (ISA), Toronto, CANADA, 09 June 2018 - 12 June 2018, http://dx.doi.org/10.1016/j.atherosclerosissup.2018.04.115
Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B; Colman PG; Best JD; Simes JR; Rye KA; Keech AC, 2017, 'Baseline Circulating FGF-21 Levels and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study', in DIABETES, AMER DIABETES ASSOC, San Diego, CA, Vol. 66, pp. A458 - A458, presented at 77th Scientific Sessions of the American-Diabetes-Association, San Diego, CA, 09 June 2017 - 13 June 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408064103220&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Wu BJ; Sun Y; Tang S; Ong KL; Barter PJ; Rye K, 2017, 'Apolipoprotein A-I Protects against Pregnancy-Induced Insulin Resistance in Rats', in DIABETES, AMER DIABETES ASSOC, San Diego, CA, Vol. 66, pp. A32 - A32, presented at 77th Scientific Sessions of the American-Diabetes-Association, San Diego, CA, 09 June 2017 - 13 June 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408064100126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cochran BJ; Hou L; Manavalan APC; Sultana A; Moore BM; Patel M; Tall A; Barter PJ; Rye KA, 2015, 'PANCREATIC BETA-CELL SPECIFIC DELETION OF ABCA1 AND ABCG1 PERTURBS GLUCOSE METABOLISM AND INCREASES ADIPOSITY IN MICE DUE TO SUBOPTIMAL PLASMA INSULIN LEVELS', in ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, Glasgow, SCOTLAND, Vol. 241, pp. E3 - E3, presented at 83rd Congress of the European-Atherosclerosis-Society (EAS), Glasgow, SCOTLAND, 22 March 2015 - 25 March 2015, http://dx.doi.org/10.1016/j.atherosclerosis.2015.04.028
Ong KL; Januszewski AS; O'Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Keech AC; Rye K-A, 2014, 'Fibroblast Growth Factor 21 and Cardiovascular Outcome Events in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study', in DIABETES, AMER DIABETES ASSOC, Vol. 63, pp. A295 - A295, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359481601456&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Ong KL; Rye K-A; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC, 2012, 'Long-term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-binding Protein 4 in Subjects With Type 2 Diabetes', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885001409&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye K-A, 2012, 'C-Reactive Protein Trends and Associations with Total Mortality in United States Adults between 1999-2010', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885000078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Wu BJ; Shrestha S; Ong KL; Johns DG; Barter PJ; Rye K-A, 2012, 'Effects of Cholesteryl Ester Transfer Protein Inhibition on Endothelial Repair and Function', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885001039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye K-A, 2011, 'Arthritis: Its Prevalence, Risk Factors, and Association with Cardiovascular Diseases in the United States National Health and Nutrition Examination Survey 1999-2008', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, Vol. 124, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299738703116&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Please contact SoMS Admin soms.info@unsw.edu.au to be added to our mail list. New SoMS staff and students are required to complete the SoMS webform as part of the data management procedure in the School.
School of Medical Sciences - Wallace Wurth Building, UNSW Sydney NSW 2052 Australia | Contacts
© Copyright 2012 UNSW Medicine | CRICOS Provider Code: 00098G | ABN 57 195 873 179 | Authorised by Head of School of Medical Sciences